CA3158221A1 - Composition and method for treating hematologic cancers - Google Patents
Composition and method for treating hematologic cancers Download PDFInfo
- Publication number
- CA3158221A1 CA3158221A1 CA3158221A CA3158221A CA3158221A1 CA 3158221 A1 CA3158221 A1 CA 3158221A1 CA 3158221 A CA3158221 A CA 3158221A CA 3158221 A CA3158221 A CA 3158221A CA 3158221 A1 CA3158221 A1 CA 3158221A1
- Authority
- CA
- Canada
- Prior art keywords
- pharmaceutically acceptable
- cancer
- cytotoxic agent
- use according
- mammalian subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 38
- 239000000203 mixture Substances 0.000 title description 17
- 201000005787 hematologic cancer Diseases 0.000 title description 4
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 104
- 201000011510 cancer Diseases 0.000 claims abstract description 67
- 229940127089 cytotoxic agent Drugs 0.000 claims abstract description 49
- 239000002254 cytotoxic agent Substances 0.000 claims abstract description 48
- 231100000599 cytotoxic agent Toxicity 0.000 claims abstract description 48
- 238000011282 treatment Methods 0.000 claims abstract description 35
- 230000002489 hematologic effect Effects 0.000 claims abstract description 28
- 150000003384 small molecules Chemical class 0.000 claims abstract description 28
- 150000003839 salts Chemical class 0.000 claims abstract description 21
- 208000003837 Second Primary Neoplasms Diseases 0.000 claims abstract description 19
- 239000012736 aqueous medium Substances 0.000 claims abstract description 16
- 108010032595 Antibody Binding Sites Proteins 0.000 claims abstract description 8
- 125000005907 alkyl ester group Chemical group 0.000 claims abstract description 8
- 239000002609 medium Substances 0.000 claims abstract description 8
- 230000034994 death Effects 0.000 claims abstract description 6
- 125000001834 xanthenyl group Chemical class C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 claims abstract 6
- 210000004027 cell Anatomy 0.000 claims description 97
- 208000032839 leukemia Diseases 0.000 claims description 37
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 15
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 15
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 15
- 208000017604 Hodgkin disease Diseases 0.000 claims description 14
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 14
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 13
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 13
- 206010025323 Lymphomas Diseases 0.000 claims description 12
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 12
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 11
- 241001465754 Metazoa Species 0.000 claims description 10
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 10
- 229930187593 rose bengal Natural products 0.000 claims description 10
- 229940081623 rose bengal Drugs 0.000 claims description 10
- STRXNPAVPKGJQR-UHFFFAOYSA-N rose bengal A Natural products O1C(=O)C(C(=CC=C2Cl)Cl)=C2C21C1=CC(I)=C(O)C(I)=C1OC1=C(I)C(O)=C(I)C=C21 STRXNPAVPKGJQR-UHFFFAOYSA-N 0.000 claims description 10
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 9
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 7
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 7
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 6
- 238000010171 animal model Methods 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 5
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 4
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims description 4
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 4
- 230000001154 acute effect Effects 0.000 claims description 4
- UWBXIFCTIZXXLS-UHFFFAOYSA-L disodium;2,3,4,5-tetrachloro-6-(2,4,5,7-tetraiodo-3-oxido-6-oxoxanthen-9-yl)benzoate Chemical compound [Na+].[Na+].[O-]C(=O)C1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1C1=C2C=C(I)C(=O)C(I)=C2OC2=C(I)C([O-])=C(I)C=C21 UWBXIFCTIZXXLS-UHFFFAOYSA-L 0.000 claims description 4
- 238000001727 in vivo Methods 0.000 claims description 4
- 241000282693 Cercopithecidae Species 0.000 claims description 3
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims description 3
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims description 3
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims description 3
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 235000013305 food Nutrition 0.000 claims description 3
- 208000003747 lymphoid leukemia Diseases 0.000 claims description 3
- AZJPTIGZZTZIDR-UHFFFAOYSA-L rose bengal Chemical compound [K+].[K+].[O-]C(=O)C1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1C1=C2C=C(I)C(=O)C(I)=C2OC2=C(I)C([O-])=C(I)C=C21 AZJPTIGZZTZIDR-UHFFFAOYSA-L 0.000 claims 4
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 2
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 2
- 239000000463 material Substances 0.000 claims 2
- 102100023990 60S ribosomal protein L17 Human genes 0.000 claims 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 1
- 150000003732 xanthenes Chemical class 0.000 description 46
- KCQREHTWEUECQT-UHFFFAOYSA-L disodium;4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-3-oxospiro[2-benzofuran-1,9'-xanthene]-3',6'-diolate Chemical compound [Na+].[Na+].O1C(=O)C(C(=C(Cl)C(Cl)=C2Cl)Cl)=C2C21C1=CC(I)=C([O-])C(I)=C1OC1=C(I)C([O-])=C(I)C=C21 KCQREHTWEUECQT-UHFFFAOYSA-L 0.000 description 36
- 239000002246 antineoplastic agent Substances 0.000 description 22
- 238000001990 intravenous administration Methods 0.000 description 20
- 231100000433 cytotoxic Toxicity 0.000 description 17
- 230000001472 cytotoxic effect Effects 0.000 description 17
- 239000003814 drug Substances 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 14
- 229940079593 drug Drugs 0.000 description 14
- 238000005286 illumination Methods 0.000 description 12
- 239000008194 pharmaceutical composition Substances 0.000 description 11
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 description 10
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 210000000987 immune system Anatomy 0.000 description 9
- 230000009885 systemic effect Effects 0.000 description 9
- IICCLYANAQEHCI-UHFFFAOYSA-N 4,5,6,7-tetrachloro-3',6'-dihydroxy-2',4',5',7'-tetraiodospiro[2-benzofuran-3,9'-xanthene]-1-one Chemical compound O1C(=O)C(C(=C(Cl)C(Cl)=C2Cl)Cl)=C2C21C1=CC(I)=C(O)C(I)=C1OC1=C(I)C(O)=C(I)C=C21 IICCLYANAQEHCI-UHFFFAOYSA-N 0.000 description 8
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 8
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 8
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 229960004528 vincristine Drugs 0.000 description 8
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 8
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 8
- 208000032800 BCR-ABL1 positive blast phase chronic myelogenous leukemia Diseases 0.000 description 7
- 208000004860 Blast Crisis Diseases 0.000 description 7
- 206010051814 Eschar Diseases 0.000 description 7
- 230000001093 anti-cancer Effects 0.000 description 7
- 230000030833 cell death Effects 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 239000003792 electrolyte Substances 0.000 description 7
- 231100000333 eschar Toxicity 0.000 description 7
- 230000028993 immune response Effects 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 231100000331 toxic Toxicity 0.000 description 7
- 230000002588 toxic effect Effects 0.000 description 7
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 6
- 229960000684 cytarabine Drugs 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 210000003714 granulocyte Anatomy 0.000 description 6
- 230000002147 killing effect Effects 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 5
- 208000009052 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 5
- 208000017414 Precursor T-cell acute lymphoblastic leukemia Diseases 0.000 description 5
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 description 5
- 208000011654 childhood malignant neoplasm Diseases 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 4
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 229930195731 calicheamicin Natural products 0.000 description 4
- HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 description 4
- 238000002512 chemotherapy Methods 0.000 description 4
- 229960000975 daunorubicin Drugs 0.000 description 4
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 4
- 229960004679 doxorubicin Drugs 0.000 description 4
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 4
- 229960005420 etoposide Drugs 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 231100000682 maximum tolerated dose Toxicity 0.000 description 4
- 238000002483 medication Methods 0.000 description 4
- 201000001441 melanoma Diseases 0.000 description 4
- 229960002621 pembrolizumab Drugs 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 238000010865 video microscopy Methods 0.000 description 4
- 206010000830 Acute leukaemia Diseases 0.000 description 3
- 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 description 3
- 208000011691 Burkitt lymphomas Diseases 0.000 description 3
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 3
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 3
- 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 206010029260 Neuroblastoma Diseases 0.000 description 3
- 230000005867 T cell response Effects 0.000 description 3
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 3
- 206010045170 Tumour lysis syndrome Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 3
- CIDNKDMVSINJCG-GKXONYSUSA-N annamycin Chemical compound I[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(=O)CO)C1 CIDNKDMVSINJCG-GKXONYSUSA-N 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 3
- 230000003828 downregulation Effects 0.000 description 3
- 229950009791 durvalumab Drugs 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 229930002330 retinoic acid Natural products 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000011269 treatment regimen Methods 0.000 description 3
- 208000010380 tumor lysis syndrome Diseases 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- HBRCDTRQDHMTDA-UHFFFAOYSA-N 2-[[4-(diethylamino)phenyl]diazenyl]benzoic acid Chemical compound C1=CC(N(CC)CC)=CC=C1N=NC1=CC=CC=C1C(O)=O HBRCDTRQDHMTDA-UHFFFAOYSA-N 0.000 description 2
- 102100033793 ALK tyrosine kinase receptor Human genes 0.000 description 2
- 101710168331 ALK tyrosine kinase receptor Proteins 0.000 description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
- 208000025321 B-lymphoblastic leukemia/lymphoma Diseases 0.000 description 2
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 2
- 241000251204 Chimaeridae Species 0.000 description 2
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 2
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 2
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 2
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 2
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 description 2
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 2
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 2
- IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 238000003349 alamar blue assay Methods 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 108010044540 auristatin Proteins 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 229960000455 brentuximab vedotin Drugs 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- 229960000928 clofarabine Drugs 0.000 description 2
- WDDPHFBMKLOVOX-AYQXTPAHSA-N clofarabine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F WDDPHFBMKLOVOX-AYQXTPAHSA-N 0.000 description 2
- 238000011284 combination treatment Methods 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 230000006882 induction of apoptosis Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000002601 intratumoral effect Effects 0.000 description 2
- 229960005386 ipilimumab Drugs 0.000 description 2
- 229960004768 irinotecan Drugs 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 201000011649 lymphoblastic lymphoma Diseases 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 210000003712 lysosome Anatomy 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 210000003071 memory t lymphocyte Anatomy 0.000 description 2
- 208000021039 metastatic melanoma Diseases 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 108010093470 monomethyl auristatin E Proteins 0.000 description 2
- 208000029986 neuroepithelioma Diseases 0.000 description 2
- 238000009521 phase II clinical trial Methods 0.000 description 2
- GVKCHTBDSMQENH-UHFFFAOYSA-L phloxine B Chemical compound [Na+].[Na+].[O-]C(=O)C1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C([O-])=C(Br)C=C21 GVKCHTBDSMQENH-UHFFFAOYSA-L 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- -1 poly(ethylene glycol) Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 208000017426 precursor B-cell acute lymphoblastic leukemia Diseases 0.000 description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 2
- 229960004618 prednisone Drugs 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 229960003787 sorafenib Drugs 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 230000036962 time dependent Effects 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- HJTAZXHBEBIQQX-UHFFFAOYSA-N 1,5-bis(chloromethyl)naphthalene Chemical compound C1=CC=C2C(CCl)=CC=CC2=C1CCl HJTAZXHBEBIQQX-UHFFFAOYSA-N 0.000 description 1
- OALHHIHQOFIMEF-UHFFFAOYSA-N 3',6'-dihydroxy-2',4',5',7'-tetraiodo-3h-spiro[2-benzofuran-1,9'-xanthene]-3-one Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(I)=C(O)C(I)=C1OC1=C(I)C(O)=C(I)C=C21 OALHHIHQOFIMEF-UHFFFAOYSA-N 0.000 description 1
- MJZJYWCQPMNPRM-UHFFFAOYSA-N 6,6-dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-1,6-dihydro-1,3,5-triazine-2,4-diamine Chemical compound CC1(C)N=C(N)N=C(N)N1OCCCOC1=CC(Cl)=C(Cl)C=C1Cl MJZJYWCQPMNPRM-UHFFFAOYSA-N 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 235000002198 Annona diversifolia Nutrition 0.000 description 1
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 238000011729 BALB/c nude mouse Methods 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241000195940 Bryophyta Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 108010008165 Etanercept Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 241000282575 Gorilla Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- 206010022095 Injection Site reaction Diseases 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 241000282842 Lama glama Species 0.000 description 1
- 235000019687 Lamb Nutrition 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 206010041660 Splenomegaly Diseases 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical group [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 206010066901 Treatment failure Diseases 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 229960002964 adalimumab Drugs 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- IMOZEMNVLZVGJZ-QGZVFWFLSA-N apremilast Chemical compound C1=C(OC)C(OCC)=CC([C@@H](CS(C)(=O)=O)N2C(C3=C(NC(C)=O)C=CC=C3C2=O)=O)=C1 IMOZEMNVLZVGJZ-QGZVFWFLSA-N 0.000 description 1
- 229960001164 apremilast Drugs 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- GOLCXWYRSKYTSP-UHFFFAOYSA-N arsenic trioxide Inorganic materials O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 description 1
- 229960003852 atezolizumab Drugs 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 229950002916 avelumab Drugs 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- UIJGNTRUPZPVNG-UHFFFAOYSA-N benzenecarbothioic s-acid Chemical compound SC(=O)C1=CC=CC=C1 UIJGNTRUPZPVNG-UHFFFAOYSA-N 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 210000003969 blast cell Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 229960003735 brodalumab Drugs 0.000 description 1
- 230000004611 cancer cell death Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000006721 cell death pathway Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229960003115 certolizumab pegol Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 238000009104 chemotherapy regimen Methods 0.000 description 1
- 208000018805 childhood acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000012191 childhood neoplasm Diseases 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000009096 combination chemotherapy Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 238000011038 discontinuous diafiltration by volume reduction Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 229940011411 erythrosine Drugs 0.000 description 1
- 235000012732 erythrosine Nutrition 0.000 description 1
- 239000004174 erythrosine Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229960000403 etanercept Drugs 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229960003297 gemtuzumab ozogamicin Drugs 0.000 description 1
- 229960001743 golimumab Drugs 0.000 description 1
- 230000002710 gonadal effect Effects 0.000 description 1
- 229950010864 guselkumab Drugs 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000000899 immune system response Effects 0.000 description 1
- 230000037449 immunogenic cell death Effects 0.000 description 1
- 231100000110 immunotoxic Toxicity 0.000 description 1
- 230000002625 immunotoxic effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000012606 in vitro cell culture Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 229960000598 infliximab Drugs 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229960005435 ixekizumab Drugs 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 206010024378 leukocytosis Diseases 0.000 description 1
- QDLAGTHXVHQKRE-UHFFFAOYSA-N lichenxanthone Natural products COC1=CC(O)=C2C(=O)C3=C(C)C=C(OC)C=C3OC2=C1 QDLAGTHXVHQKRE-UHFFFAOYSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 210000003519 mature b lymphocyte Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 229940124303 multikinase inhibitor Drugs 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229960003301 nivolumab Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 210000004287 null lymphocyte Anatomy 0.000 description 1
- 229950007318 ozogamicin Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 238000002135 phase contrast microscopy Methods 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229950010773 pidilizumab Drugs 0.000 description 1
- 229940126621 pogalizumab Drugs 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 201000006845 reticulosarcoma Diseases 0.000 description 1
- 208000029922 reticulum cell sarcoma Diseases 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 229950006348 sarilumab Drugs 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 229960004540 secukinumab Drugs 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 230000007474 system interaction Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 229950007217 tremelimumab Drugs 0.000 description 1
- 239000000439 tumor marker Substances 0.000 description 1
- 230000037455 tumor specific immune response Effects 0.000 description 1
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 1
- 229960003824 ustekinumab Drugs 0.000 description 1
- 231100000747 viability assay Toxicity 0.000 description 1
- 238000003026 viability measurement method Methods 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
- 229940055760 yervoy Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
A method of treating a mammalian subject having hematologic, non-tumorous cancer cells is disclosed. The method comprises the steps of: (A) administering to such a mammalian subject a therapeutically effective amount of a halogenated xanthene, a pharmaceutically acceptable salt or a C2-C4 alkyl ester thereof as a first cancer cytotoxic agent dissolved or dispersed in a pharmaceutically acceptable aqueous medium. The mammalian subject is maintained for a period of time sufficient to induce death of hematologic, non-tumorous cancer cells. A contemplated administration is typically repeated, A contemplated treatment method can also be carried out in conjunction with administration to said mammalian subject of a second therapeutically effective amount of a second, differently-acting cancer cytotoxic agent dissolved or dispersed in a pharmaceutically acceptable medium, The second cancer cytotoxic agent can be a small molecule or an intact antibody or paratope-containing portion thereof.
Description
COMPOSITION AND METHOD FOR
TREATING HEMATOLOGIC CANCERS
Description Field of the Invention This invention relates to a therapeutic regimen for treating blood (hematologic) cancers such as leukemia, lymphoma, and multiple myeloma, and particularly effecting such treatments in children.
BACKGROUND ART
An adult human has about 7000 white blood cells per microliter ( L) of blood. Of those white cells, about 65 percent are granulocytes (about 4500/ L) , about 30 percent are monocytes (about 2100/ pi) and about five percent are lymphocytes (about 350/ EiL) . Geyton, Textbook of Medical Physiology, Seventh ed., W. B. Saunders Co., Philadelphia (1986).
The above cell numbers are, of course, generalized average values, and granulocyte counts for normal patients; i.e., patients free of disease, typically have granulocyte counts of about 2000 to about 7000 cells/ L.
Chronic myelogenous leukemia (CML), also known as chronic granulocytic leukemia (CGL), is a neoplastic disorder of the hematopoietic stem cell. In its early phases it is characterized by leukocytosis, - the presence of increased numbers of immature granulocytes in the peripheral blood, splenomegaly and anemia. These immature granulocytes include basophils, eosinophils, and neutrophils. The immature granulocytes also accumulate in the bone marrow, spleen, liver, and occasionally in other tissues.
Patients presenting with this disease characteristically have more than 75,000 white blood cells per microliter ( L), and the count can exceed 500,000/ L.
CML accounts for about 20 percent of all leukemias in the United States. About 15 new cases per million people are reported each year, leading to about 3,000 to 4,000 new cases per year. The disease is rare in humans below age 45, rises rapidly to age 65, and remains high thereafter. The median life span of patients with chronic myelogenous leukemia from the time of diagnosis is approximately four years.
About 60 to 80 percent of patients with CML
develop a blast crisis. Blast crisis represents a manifestation of acute leukemia. The presence of certain markers on the blast cells sometimes suggests a lymphold origin of these cells during the blast crisis.
Chemotherapeutic agents used for the treatment of the blast crisis are the same as those used for the treatment of other acute leukemias. For example, cytarabine and daunorubicin, used for the treatment of acute myelocytic leukemia, are used to treat CML blast crisis. Prednisone and vincristine, a therapeutic regime used in the treatment of acute lymphocytic leukemias, is also used to treat CML blast crisis. Nevertheless, these drug therapies of the blast crisis stage of CML are even less successful than are the treatments of other acute leukemias.
TREATING HEMATOLOGIC CANCERS
Description Field of the Invention This invention relates to a therapeutic regimen for treating blood (hematologic) cancers such as leukemia, lymphoma, and multiple myeloma, and particularly effecting such treatments in children.
BACKGROUND ART
An adult human has about 7000 white blood cells per microliter ( L) of blood. Of those white cells, about 65 percent are granulocytes (about 4500/ L) , about 30 percent are monocytes (about 2100/ pi) and about five percent are lymphocytes (about 350/ EiL) . Geyton, Textbook of Medical Physiology, Seventh ed., W. B. Saunders Co., Philadelphia (1986).
The above cell numbers are, of course, generalized average values, and granulocyte counts for normal patients; i.e., patients free of disease, typically have granulocyte counts of about 2000 to about 7000 cells/ L.
Chronic myelogenous leukemia (CML), also known as chronic granulocytic leukemia (CGL), is a neoplastic disorder of the hematopoietic stem cell. In its early phases it is characterized by leukocytosis, - the presence of increased numbers of immature granulocytes in the peripheral blood, splenomegaly and anemia. These immature granulocytes include basophils, eosinophils, and neutrophils. The immature granulocytes also accumulate in the bone marrow, spleen, liver, and occasionally in other tissues.
Patients presenting with this disease characteristically have more than 75,000 white blood cells per microliter ( L), and the count can exceed 500,000/ L.
CML accounts for about 20 percent of all leukemias in the United States. About 15 new cases per million people are reported each year, leading to about 3,000 to 4,000 new cases per year. The disease is rare in humans below age 45, rises rapidly to age 65, and remains high thereafter. The median life span of patients with chronic myelogenous leukemia from the time of diagnosis is approximately four years.
About 60 to 80 percent of patients with CML
develop a blast crisis. Blast crisis represents a manifestation of acute leukemia. The presence of certain markers on the blast cells sometimes suggests a lymphold origin of these cells during the blast crisis.
Chemotherapeutic agents used for the treatment of the blast crisis are the same as those used for the treatment of other acute leukemias. For example, cytarabine and daunorubicin, used for the treatment of acute myelocytic leukemia, are used to treat CML blast crisis. Prednisone and vincristine, a therapeutic regime used in the treatment of acute lymphocytic leukemias, is also used to treat CML blast crisis. Nevertheless, these drug therapies of the blast crisis stage of CML are even less successful than are the treatments of other acute leukemias.
-2-Cancer in children is rare with an incidence of 140-155 per million per year (age million per year (age <15 years). This translates to -1 in 7,000 children is diagnosed with cancer each year. Despite the rarity of cancer, malignant neoplasm is the most common cause of death after accidents in children aged to 14 years, accounting for 23% of mortality.
Survival from childhood cancers, many of which were fatal in the pre-chemotherapy era, has increased dramatically from 20-30% in the 1960s to 62% in the 1970s, and more recently to 83%. Saletta et al., Transl Pediatr 3(2):156-182 (2014).
Leukemias are the most common childhood cancers, accounting for about 30% of all pediatric (ages 1-14) cancer diagnoses. Acute lymphoblastic leukemia (ALL) accounts for about 25% of ohildrens' cancers, and acute myeloid leukemia (AML) accounts for the remaining about 5%. Non-hodgkin lymphoma (NHL) and Hodgkin lymphoma account for about 6 and about 4 % of childhood cancers, respectively. (Ibid.) Current treatments for ALL include pegylated asparginase, liposomal daunorubicin, liposomal annamycin, sphingosomal vincristine and liposomal cytarabine. For AML, current treatments include the use of all-trans-retinoic acid (ATRA), arsenic trioxide, anthracycline combined with ATRA, and idarubicin with high-dose cytarabine. Sorafenib (multikinase inhibitor) in combination with clofarabine and cytarabine has found success in a phase I study [
Inaba et al., J din Oncol 29:3293-3300 (2011)], and a calicheamicin-conjugated CD33 antibody, gemtuzumab
Survival from childhood cancers, many of which were fatal in the pre-chemotherapy era, has increased dramatically from 20-30% in the 1960s to 62% in the 1970s, and more recently to 83%. Saletta et al., Transl Pediatr 3(2):156-182 (2014).
Leukemias are the most common childhood cancers, accounting for about 30% of all pediatric (ages 1-14) cancer diagnoses. Acute lymphoblastic leukemia (ALL) accounts for about 25% of ohildrens' cancers, and acute myeloid leukemia (AML) accounts for the remaining about 5%. Non-hodgkin lymphoma (NHL) and Hodgkin lymphoma account for about 6 and about 4 % of childhood cancers, respectively. (Ibid.) Current treatments for ALL include pegylated asparginase, liposomal daunorubicin, liposomal annamycin, sphingosomal vincristine and liposomal cytarabine. For AML, current treatments include the use of all-trans-retinoic acid (ATRA), arsenic trioxide, anthracycline combined with ATRA, and idarubicin with high-dose cytarabine. Sorafenib (multikinase inhibitor) in combination with clofarabine and cytarabine has found success in a phase I study [
Inaba et al., J din Oncol 29:3293-3300 (2011)], and a calicheamicin-conjugated CD33 antibody, gemtuzumab
-3-ozogamicin, known commercially as MylotargO, has shown promise [Zwaan et al., Br J Baemato1 148:768-776 (2010)].
Unlike adults, in whom non-Hodgkin's lymphoma (NHL) is generally low/intermediate grade, pediatric NHL is frequently high grade. NHL can be classified according to phenotype (B-cell vs. T-cell) and differentiation. It falls into three categories: (I) mature B-cell NHL including Burkitt/Burkitt-like lymphoma and diffuse large B-cell lymphoma (DLBCL);
(II) lymphoblastic lymphoma (LL) (mostly precursor T-cell); and (III) anaplastic large cell lymphoma (ALCL) (mature T-cell or null-cell). Burkitt lymphoma (BL) is most common, accounting for one-third of pediatric NHL [Saletta et al., Transl Pediatr 3(2):156-182 (2014)1.
Rituximab (CD 20 antibody) alone and in conjunction with chemotherapy has been undergoing trials in patients with BL and DLBCL [windebank et al., Pediatr Blood Cancer 53:392-396 (2009); and Gross et al., Am J Transplant 12:3069-3075 (2012)]. Brentuximab vedotin a chimer of CD30 antibody and monomethyl auristatin E has shown positive responses and remissions in adult phase II trials [Pro et al., J din Oncol 30:2190-2196 (2012)], whereas erizotinib and ALK (anaplastic lymphoma kinase) inhibitor elicited positive responses in 8/9 ALCL patients in a phase I study [Mosse' et al., Lancet Oncol 14:472-480 (2013)1.
Hodgkin's lymphoma (HL) is the most common cancer in the 15 to 19 years age group and is four to five times more frequent than in the <15 years age
Unlike adults, in whom non-Hodgkin's lymphoma (NHL) is generally low/intermediate grade, pediatric NHL is frequently high grade. NHL can be classified according to phenotype (B-cell vs. T-cell) and differentiation. It falls into three categories: (I) mature B-cell NHL including Burkitt/Burkitt-like lymphoma and diffuse large B-cell lymphoma (DLBCL);
(II) lymphoblastic lymphoma (LL) (mostly precursor T-cell); and (III) anaplastic large cell lymphoma (ALCL) (mature T-cell or null-cell). Burkitt lymphoma (BL) is most common, accounting for one-third of pediatric NHL [Saletta et al., Transl Pediatr 3(2):156-182 (2014)1.
Rituximab (CD 20 antibody) alone and in conjunction with chemotherapy has been undergoing trials in patients with BL and DLBCL [windebank et al., Pediatr Blood Cancer 53:392-396 (2009); and Gross et al., Am J Transplant 12:3069-3075 (2012)]. Brentuximab vedotin a chimer of CD30 antibody and monomethyl auristatin E has shown positive responses and remissions in adult phase II trials [Pro et al., J din Oncol 30:2190-2196 (2012)], whereas erizotinib and ALK (anaplastic lymphoma kinase) inhibitor elicited positive responses in 8/9 ALCL patients in a phase I study [Mosse' et al., Lancet Oncol 14:472-480 (2013)1.
Hodgkin's lymphoma (HL) is the most common cancer in the 15 to 19 years age group and is four to five times more frequent than in the <15 years age
- 4 --group. HL is typically categorized into classical and nodular lymphocyte predominant HL.
HL was fatal until the 1960s when the MOPP
(nitrogen mustard, vincristine, procarbazine and prednisone-containing) chemotherapy regimen was introduced. The cure rate of HL in children has been >90% in the last two decades and is one of the most curable childhood cancers. Unfortunately, survivors of childhood HL are at significant risk of long-term treatment-related morbidity and mortality.
Earlier treatments typically included use of radiation along with chemotherapy, which increased the subsequent finding increased breast cancers in previously treated women. More modern approaches have limited use of radiation in patients in complete response after two cycles of chemotherapy referred to as rapid early responder (PER), omission of involved-field radiation therapy (IFIRT) in low risk RER, and gender-based modification of treatment to utilize less gonadal toxic alkylating therapy in males ad avoiding IFRT in females.
Although the survival rate for pediatric leukemia has greatly improved, relapse is a major cause of treatment failure. Approximately 15-20% of pediatric ALL patients and 30-40% of AML patients relapse, with relapsed ALL identified as the fourth most common malignancy in children.
Treatment of relapsed pediatric leukemia includes intensification of chemotherapeutic regimens and use of bone marrow transplantation (EMT). However, increasing the intensity of combination chemotherapies and introduction of second-line drugs is often
HL was fatal until the 1960s when the MOPP
(nitrogen mustard, vincristine, procarbazine and prednisone-containing) chemotherapy regimen was introduced. The cure rate of HL in children has been >90% in the last two decades and is one of the most curable childhood cancers. Unfortunately, survivors of childhood HL are at significant risk of long-term treatment-related morbidity and mortality.
Earlier treatments typically included use of radiation along with chemotherapy, which increased the subsequent finding increased breast cancers in previously treated women. More modern approaches have limited use of radiation in patients in complete response after two cycles of chemotherapy referred to as rapid early responder (PER), omission of involved-field radiation therapy (IFIRT) in low risk RER, and gender-based modification of treatment to utilize less gonadal toxic alkylating therapy in males ad avoiding IFRT in females.
Although the survival rate for pediatric leukemia has greatly improved, relapse is a major cause of treatment failure. Approximately 15-20% of pediatric ALL patients and 30-40% of AML patients relapse, with relapsed ALL identified as the fourth most common malignancy in children.
Treatment of relapsed pediatric leukemia includes intensification of chemotherapeutic regimens and use of bone marrow transplantation (EMT). However, increasing the intensity of combination chemotherapies and introduction of second-line drugs is often
-5-accompanied by cumulative toxicity with marginal incremental benefits.
A key component for understanding immune system interactions against pediatric cancers is the availability of an applicable animal model. Current xenograft models are limited because they are established in severe combined immunodeficient (SCID) mice and so do not provide information on the contribution of the immune system. Other approaches such as human hematopoietic stem cell reconstitution in immunocompetent animals are cumbersome, expensive and often introduce complex biological variables into the system.
Recently, a novel xenograft tumor model was developed in immunocompetent mice by tolerizing mice fetuses to human tumor cells [Basel et al., Cancer Lett. 412:256-263 (2018)]. This model is advantageous because it can be used to better describe the complex interaction between cancerous cells and the immune system through a xenograft technique.
One useful anti-cancer agent group for adult cancerous tumors are the halogenated xanthenes, or the pharmaceutically acceptable salts thereof. See, US
Patents No. 6,331,286, No. 7,390,668, No. 7,648,695, No. 9,107,887, No. 9,808,524, No. 9,839,688, and No.
10,130,658. Of those halogenated xanthenes, Rose Bengal disodium, (4,5,6,7-tetrachloro-2',4',5',7'-tetraiodofluorescein disodium; RB) has been found to be particularly effective and easily utilized.
PV-10 is a sterile 10% solution of RB in 0.9%
saline that has been used clinically to measure liver function in infants [Yvart et al., Eur J Nucl _Pied
A key component for understanding immune system interactions against pediatric cancers is the availability of an applicable animal model. Current xenograft models are limited because they are established in severe combined immunodeficient (SCID) mice and so do not provide information on the contribution of the immune system. Other approaches such as human hematopoietic stem cell reconstitution in immunocompetent animals are cumbersome, expensive and often introduce complex biological variables into the system.
Recently, a novel xenograft tumor model was developed in immunocompetent mice by tolerizing mice fetuses to human tumor cells [Basel et al., Cancer Lett. 412:256-263 (2018)]. This model is advantageous because it can be used to better describe the complex interaction between cancerous cells and the immune system through a xenograft technique.
One useful anti-cancer agent group for adult cancerous tumors are the halogenated xanthenes, or the pharmaceutically acceptable salts thereof. See, US
Patents No. 6,331,286, No. 7,390,668, No. 7,648,695, No. 9,107,887, No. 9,808,524, No. 9,839,688, and No.
10,130,658. Of those halogenated xanthenes, Rose Bengal disodium, (4,5,6,7-tetrachloro-2',4',5',7'-tetraiodofluorescein disodium; RB) has been found to be particularly effective and easily utilized.
PV-10 is a sterile 10% solution of RB in 0.9%
saline that has been used clinically to measure liver function in infants [Yvart et al., Eur J Nucl _Pied
-6-6:355-359 (1981)]. Previous studies have shown that PV-10 accumulates in cancer cell lysosomes [Wachter, et al., Proceedings or SPIE, Multiphoton Microscopy in the Biomedical Sciences II, Periasamy, A. and So, P.T.C.
(eds), Bellingham, Washington: 4620: 143-147 (2002)]
and induces cell death in a range of adult cancers [Qin et al., Cell Death Dis 8:e2584 (2017); Toomey et al., FLoS ONE 8(7):e68561 (2013); Koevary et al., Int J
Physiol Pathophysiol Pharmaco1 4(2):99-107 (2012);
Thompson et al., Melanoma Res 18(6):405-411 (2008); and Zamani et al., J Immunotoxic 11(4):367-375 (2014)].
PV-10 has been used in a number of clinical trials, both as a single anti-cancer agent and in conjunction with both small molecule and monoclonal antibody anti-cancer agents. Several of those trials are discussed below. Phase I and phase IT clinical studies using PV-10 alone as the cytotoxic agent illustratively reported "adverse events were predominantly mild to moderate and locoregional to the treatment site, with no treatment-associated grade 4 or adverse events" [Thompson et al., Ann Surg Oncol 22(7):2135-2142 (2015)11 and "Treatment-Emergent Adverse Events (TEAEs) were consistent with established patterns for each drug, principally Grade 1-2 injection site reactions attributed to PV-10 and Grade 1-3 immune-mediated reactions attributed to pembrolizumab, with no significant overlap or unexpected toxicities:
. " [Agarwala et al., J din Oncol 37(15) suppl 9559-9559 (May 26, 2019)1. It thus appears as though RB is toxic to cancerous cells, but non-toxic to non-cancerous cells.
(eds), Bellingham, Washington: 4620: 143-147 (2002)]
and induces cell death in a range of adult cancers [Qin et al., Cell Death Dis 8:e2584 (2017); Toomey et al., FLoS ONE 8(7):e68561 (2013); Koevary et al., Int J
Physiol Pathophysiol Pharmaco1 4(2):99-107 (2012);
Thompson et al., Melanoma Res 18(6):405-411 (2008); and Zamani et al., J Immunotoxic 11(4):367-375 (2014)].
PV-10 has been used in a number of clinical trials, both as a single anti-cancer agent and in conjunction with both small molecule and monoclonal antibody anti-cancer agents. Several of those trials are discussed below. Phase I and phase IT clinical studies using PV-10 alone as the cytotoxic agent illustratively reported "adverse events were predominantly mild to moderate and locoregional to the treatment site, with no treatment-associated grade 4 or adverse events" [Thompson et al., Ann Surg Oncol 22(7):2135-2142 (2015)11 and "Treatment-Emergent Adverse Events (TEAEs) were consistent with established patterns for each drug, principally Grade 1-2 injection site reactions attributed to PV-10 and Grade 1-3 immune-mediated reactions attributed to pembrolizumab, with no significant overlap or unexpected toxicities:
. " [Agarwala et al., J din Oncol 37(15) suppl 9559-9559 (May 26, 2019)1. It thus appears as though RB is toxic to cancerous cells, but non-toxic to non-cancerous cells.
-7 -Because of the often-times very different behavior of adult tumors from pediatric tumors, it was not known whether RB and similar halogenated xanthenes would be effective when used against pediatric cancerous cells, and particularly cancerous hematologic cells. Preliminary in vitro and xenograft studies against neuroblastoma cell lines in cell cultures to which RB was added alone or in conjunction with known anticancer agents, and by intralesional injection in mice, respectively, were reported by one of the present inventors and co-workers to exhibit killing of the cancerous cells. Swift et al., Oncotargets Ther, 12:1293-1307 (February 2019).
In addition, intralesional administration of a halogenated xanthene into a tumor provides the active cytotoxic agent directly to the tumor at its highest concentration. In a presently contemplated treatment technique discussed below, administration is often distant from the target cancerous hematiologic cells, thereby possibly diminishing the effectiveness of the cancerocidal halogenated xanthene agent.
However, in a phase II clinical trial for patients with refractory metastatic melanoma, intralesional (IL) injection of PV-10 induced tumor regression with an overall response rate of 51%
[Thompson et al., Ann Surg Oncol 22(7):2135-2142 (2015)]. PV-10 also demonstrated efficacy in combination with radiotherapy in a phase II clinical trial for patients with in-transit or metastatic melanoma, with an overall response rate of 86.6% [Foote et al., J Surg Oncol 115(7): 891-897 (2017)].
In addition, intralesional administration of a halogenated xanthene into a tumor provides the active cytotoxic agent directly to the tumor at its highest concentration. In a presently contemplated treatment technique discussed below, administration is often distant from the target cancerous hematiologic cells, thereby possibly diminishing the effectiveness of the cancerocidal halogenated xanthene agent.
However, in a phase II clinical trial for patients with refractory metastatic melanoma, intralesional (IL) injection of PV-10 induced tumor regression with an overall response rate of 51%
[Thompson et al., Ann Surg Oncol 22(7):2135-2142 (2015)]. PV-10 also demonstrated efficacy in combination with radiotherapy in a phase II clinical trial for patients with in-transit or metastatic melanoma, with an overall response rate of 86.6% [Foote et al., J Surg Oncol 115(7): 891-897 (2017)].
-8-In addition to inducing direct cancer cell death, PV-10 has also been shown to induce a tumor-specific immune response in both mouse studies [Qin et al., Cell Death This 8:e2584 (2017); Toomey et al., PLoS
ONE 8(7):e68561 (2013); and Liu et al., Oncotarget 7(25):37893-37905 (2016)] and human clinical trials fLippey et al., J Surg Oncol 114(3):380-384 (2016);
Ross, J Surg Oncol 109(4):314-319 (2104); Liu et al., PLoS ONE 13(4):e0196033 (2018); andBasel et al., Cancer Lett 412:256-263 (2018)]. In murine models of melanoma, treatment with PV-10 induced necrosis of melanoma cells and a localized increase in mononuclear tumor-infiltrating lymphocytes [Lippey et al., J Surg Oncol 114(3):380-384 (2016)].
It has been suggested that PV-10-induced immunogenic cell death, releasing tumor antigens to nearby antigen-presenting cells (APCs), facilitated the activating of anti-tumor T and B cells. In a syngeneic murine colon cancer model, injection of cancer cells treated in vitro with PV-10 into mice with the same tumor resulted in slower tumor growth [Oin et al., Cell Death Dis 8:e2534 (2017)]. Furthermore, in syngeneic murine melanoma models, combination treatment with intralesional PV-10 and anti-PD1 antibody delayed tumor growth and enhanced T cell activation [Liu et al., PLoS
ONE 13(4):e0196033 (2108)].
The disclosure below describes the contemplated invention and provides results of studies using halogenated xanthenes such as PV-10 in the treatment of pediatric leukemias.
ONE 8(7):e68561 (2013); and Liu et al., Oncotarget 7(25):37893-37905 (2016)] and human clinical trials fLippey et al., J Surg Oncol 114(3):380-384 (2016);
Ross, J Surg Oncol 109(4):314-319 (2104); Liu et al., PLoS ONE 13(4):e0196033 (2018); andBasel et al., Cancer Lett 412:256-263 (2018)]. In murine models of melanoma, treatment with PV-10 induced necrosis of melanoma cells and a localized increase in mononuclear tumor-infiltrating lymphocytes [Lippey et al., J Surg Oncol 114(3):380-384 (2016)].
It has been suggested that PV-10-induced immunogenic cell death, releasing tumor antigens to nearby antigen-presenting cells (APCs), facilitated the activating of anti-tumor T and B cells. In a syngeneic murine colon cancer model, injection of cancer cells treated in vitro with PV-10 into mice with the same tumor resulted in slower tumor growth [Oin et al., Cell Death Dis 8:e2534 (2017)]. Furthermore, in syngeneic murine melanoma models, combination treatment with intralesional PV-10 and anti-PD1 antibody delayed tumor growth and enhanced T cell activation [Liu et al., PLoS
ONE 13(4):e0196033 (2108)].
The disclosure below describes the contemplated invention and provides results of studies using halogenated xanthenes such as PV-10 in the treatment of pediatric leukemias.
-9-BRIEF SUMMARY OF THE INVENTION
The present invention contemplates a method of treating a mammalian subject having hematologic, non-tumorous cancer cell. Illustrative hematologic, non-tumorous cancers include leukemia, lymphoma and myeloma. The method comprises the steps of: (A) administering to such a mammalian subject a therapeutically effective amount of a halogenated xanthene, a pharmaceutically acceptable salt or a 01-04 alkyl ester thereof as a first cancer cytotoxic agent dissolved or dispersed in a pharmaceutically acceptable aqueous medium. The mammalian subject is maintained for a period of time sufficient to induce death of hematologic, non-tumorous cancer cells. A contemplated administration is typically repeated.
A contemplated treatment method can also be carried out in conjunction with administration to that mammalian subject of a second therapeutically effective amount of a second, differently-acting cancer cytotoxic agent dissolved or dispersed in a pharmaceutically acceptable medium_ The second cancer cytotoxic agent can be a small molecule or an intact antibody or paratope-containing antibody portion. The first and the second cancer cytotoxic agents can be administered together in the same or different media, or at different times. The second cancer cytotoxic agent can be administered in a solid tablet, capsule, pill or the like or in a liquid medium.
In one aspect, use of a small molecule cancer cytotoxic agent having a molecular weight of about 200 to about 1000 pa is contemplated. Compounds that
The present invention contemplates a method of treating a mammalian subject having hematologic, non-tumorous cancer cell. Illustrative hematologic, non-tumorous cancers include leukemia, lymphoma and myeloma. The method comprises the steps of: (A) administering to such a mammalian subject a therapeutically effective amount of a halogenated xanthene, a pharmaceutically acceptable salt or a 01-04 alkyl ester thereof as a first cancer cytotoxic agent dissolved or dispersed in a pharmaceutically acceptable aqueous medium. The mammalian subject is maintained for a period of time sufficient to induce death of hematologic, non-tumorous cancer cells. A contemplated administration is typically repeated.
A contemplated treatment method can also be carried out in conjunction with administration to that mammalian subject of a second therapeutically effective amount of a second, differently-acting cancer cytotoxic agent dissolved or dispersed in a pharmaceutically acceptable medium_ The second cancer cytotoxic agent can be a small molecule or an intact antibody or paratope-containing antibody portion. The first and the second cancer cytotoxic agents can be administered together in the same or different media, or at different times. The second cancer cytotoxic agent can be administered in a solid tablet, capsule, pill or the like or in a liquid medium.
In one aspect, use of a small molecule cancer cytotoxic agent having a molecular weight of about 200 to about 1000 pa is contemplated. Compounds that
-10-synergize with a halogenated xanthene such as doxorubicin, etoposide and vincristine are preferred.
Intact antibodies or paratope-containing antibody portions are a second group of cancer cytotoxic agents.
Preferred among these agents are those referred to as immune check point inhibitors. [See, for example, Darvin et al., Exp Hal Med, 50:165 (2018).]
The present invention also contemplates use of a therapeutically effective amount of a halogenated xanthene, a pharmaceutically acceptable salt or a Ci-C4 alkyl ester thereof as a first cancer cytotoxic agent dissolved or dispersed in a pharmaceutically acceptable aqueous medium for treatment of a mammalian subject having hematologic, non-tumorous cancer cells, wherein the halogenated xanthene is maintained in the mammalian subject for a period of time sufficient to induce death of hematologic, non-tumorous cancer cells. In a further embodiment, the first cancer cytotoxic agent halogenated xanthene, pharmaceutically acceptable salt or C1-04 alkyl ester thereof is rose bengal, a pharmaceutically acceptable salt or C1-C4 alkyl ester thereof. In a still further embodiment, the rose bengal is rose bengal disodium salt. Further, the hematologic, non-tumorous cancer cells are leukemia, lymphoma or myeloma. Further, the hematologic, non-tumorous cancer cells, leukemia, lymphoma or myeloma is selected from the group consisting of acute B-cell or T-cell lymphoblastic leukemia, acute myeloid leukemia, non-Hodgkin's lymphoma, and Hodgkin's lymphoma.
Intact antibodies or paratope-containing antibody portions are a second group of cancer cytotoxic agents.
Preferred among these agents are those referred to as immune check point inhibitors. [See, for example, Darvin et al., Exp Hal Med, 50:165 (2018).]
The present invention also contemplates use of a therapeutically effective amount of a halogenated xanthene, a pharmaceutically acceptable salt or a Ci-C4 alkyl ester thereof as a first cancer cytotoxic agent dissolved or dispersed in a pharmaceutically acceptable aqueous medium for treatment of a mammalian subject having hematologic, non-tumorous cancer cells, wherein the halogenated xanthene is maintained in the mammalian subject for a period of time sufficient to induce death of hematologic, non-tumorous cancer cells. In a further embodiment, the first cancer cytotoxic agent halogenated xanthene, pharmaceutically acceptable salt or C1-04 alkyl ester thereof is rose bengal, a pharmaceutically acceptable salt or C1-C4 alkyl ester thereof. In a still further embodiment, the rose bengal is rose bengal disodium salt. Further, the hematologic, non-tumorous cancer cells are leukemia, lymphoma or myeloma. Further, the hematologic, non-tumorous cancer cells, leukemia, lymphoma or myeloma is selected from the group consisting of acute B-cell or T-cell lymphoblastic leukemia, acute myeloid leukemia, non-Hodgkin's lymphoma, and Hodgkin's lymphoma.
-11-DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS
In one aspect, the present invention contemplates a pharmaceutical composition for use in the treatment (killing) of hematologic, non-tumorous cancer cells, e.g., leukemia, lymphoma and myeioma. A
contemplated pharmaceutical composition comprises a 0.1 % to about 20 % (w/v) aqueous medium (as a liquid) of a first cancer cytotoxic agent that is a halogenated xanthene, a physiologically acceptable salt of the halogenated xanthene, or a C1-C4 alkyl ester thereof.
A particularly preferred halogenated xanthene salt is rose bengal (4,5,6,7-tetrachloro-2',4',5',7t-tetraiodofluorescein) disodium salt, as is present in PV-10. The composition is administered to provide a therapeutically effective amount of a first cancer cytotoxic agent to a mammal such as a human having a hematologic, non-tumorous cancerous disease such as leukemia, lymphoma and myeloma, or more specifically, acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), non-Hodgkin's lymphoma (NHL), or Hodgkin's lymphoma (HL).
The mammalian subject is maintained for a time sufficient to kill hematologic, non-tumorous cancerous cells. The fact and relative amount of cancer killing can be determined by usual means for assaying the status of hematologic, non-tumorous cancers.
The mammalian subject is typically thereafter treated again, usually multiple times. Both the duration of maintenance and the choice to conduct further administrations can depend upon the species of
In one aspect, the present invention contemplates a pharmaceutical composition for use in the treatment (killing) of hematologic, non-tumorous cancer cells, e.g., leukemia, lymphoma and myeioma. A
contemplated pharmaceutical composition comprises a 0.1 % to about 20 % (w/v) aqueous medium (as a liquid) of a first cancer cytotoxic agent that is a halogenated xanthene, a physiologically acceptable salt of the halogenated xanthene, or a C1-C4 alkyl ester thereof.
A particularly preferred halogenated xanthene salt is rose bengal (4,5,6,7-tetrachloro-2',4',5',7t-tetraiodofluorescein) disodium salt, as is present in PV-10. The composition is administered to provide a therapeutically effective amount of a first cancer cytotoxic agent to a mammal such as a human having a hematologic, non-tumorous cancerous disease such as leukemia, lymphoma and myeloma, or more specifically, acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), non-Hodgkin's lymphoma (NHL), or Hodgkin's lymphoma (HL).
The mammalian subject is maintained for a time sufficient to kill hematologic, non-tumorous cancerous cells. The fact and relative amount of cancer killing can be determined by usual means for assaying the status of hematologic, non-tumorous cancers.
The mammalian subject is typically thereafter treated again, usually multiple times. Both the duration of maintenance and the choice to conduct further administrations can depend upon the species of
-12-mammal, individual mammalian subjects, the severity of disease, type of disease, age and health of the subject, and the like. These factors are commonly dealt with by physicians skilled in the art of treating hematologic, non-tumorous cancers.
In addition, whereas it is typically desired to rid the body of detectable cancerous cells, that cannot always be done. Sometimes it is sufficient to kill enough cancerous cells to control the disease in stasis, or to reduce the cancerous load of cells so that other therapies can be carried out.
The data provided hereinafter illustrates that the I050 value for use of RB against several leukemia cell lines in vitro is about 50 to about 100 M. Given that the molecular weight of RB is 1018 g/mole, the above 1050 value calculates to about 50 to about 100 mg of RB/liter. It is preferred to achieve that concentration for contacting cancerous cells during an in vivo treatment.
The classic intravenous (IV) diagnostic use of RB was conducted giving 100 mg RB as a single IV
dose. In clinical studies of PV-10, RB has been tolerated at 1500 mg delivered IV. The standard adult blood volume is approximately 5 L. Thus, to achieve 100 mg/L in the blood, an adult patient would need to receive approximately 500 mg of RB IV to achieve the 1050 value in the bloodstream. Due to the rapid clearance of RB from circulation (t1/2 is about 30 minutes), an IV administration would require continuous infusion to maintain peak levels of RB in circulation (i.e., for up to several hours or more).
In addition, whereas it is typically desired to rid the body of detectable cancerous cells, that cannot always be done. Sometimes it is sufficient to kill enough cancerous cells to control the disease in stasis, or to reduce the cancerous load of cells so that other therapies can be carried out.
The data provided hereinafter illustrates that the I050 value for use of RB against several leukemia cell lines in vitro is about 50 to about 100 M. Given that the molecular weight of RB is 1018 g/mole, the above 1050 value calculates to about 50 to about 100 mg of RB/liter. It is preferred to achieve that concentration for contacting cancerous cells during an in vivo treatment.
The classic intravenous (IV) diagnostic use of RB was conducted giving 100 mg RB as a single IV
dose. In clinical studies of PV-10, RB has been tolerated at 1500 mg delivered IV. The standard adult blood volume is approximately 5 L. Thus, to achieve 100 mg/L in the blood, an adult patient would need to receive approximately 500 mg of RB IV to achieve the 1050 value in the bloodstream. Due to the rapid clearance of RB from circulation (t1/2 is about 30 minutes), an IV administration would require continuous infusion to maintain peak levels of RB in circulation (i.e., for up to several hours or more).
-13-Administration at the IC50 value level would not be toxic to all circulating hematologic, non-tumorous cancerous cells; i.e., only approximately half of cells would be affected at the 1050 value. It can therefore be preferred to administer RB at a multiple of the IC50 value, up to approximately 1500 mg (i.e., 300 M).
Alternatively, it can be sufficient to kill only a fraction of the cancerous cells to initiate a functional immune response against remaining tumor burden. The latter case can be preferable to avoid toxic reaction (i.e., so-called "tumor lysis syndrome"
due to presence of an abundance of rapidly killed cancer cells. In this situation, the cancer cell debris caused by the cytotoxicity to cancer cells of a halogenated xanthene induces an immune reaction that in turn kills further cancerous hematologic, non-tumorous cells.
The similarly useful halogenated xanthene compounds listed below and their pharmaceutically acceptable salts can have molecular weights that differ from each other by about a factor of three (See, Table 3, US Patent No. 7,390,688 at columns 15-16). It is preferred that an exact amount of other than RB
halogenated xanthene to be used is calculated based on published molecular weights for each such compound and that of RB.
A contemplated halogenated xanthene includes rose bengal (4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-fluorescein) that is particularly preferred, erythrosin B, phloxine B, 4,5,6,7-tetrabromo-2',4',5',7'-tetra-
Alternatively, it can be sufficient to kill only a fraction of the cancerous cells to initiate a functional immune response against remaining tumor burden. The latter case can be preferable to avoid toxic reaction (i.e., so-called "tumor lysis syndrome"
due to presence of an abundance of rapidly killed cancer cells. In this situation, the cancer cell debris caused by the cytotoxicity to cancer cells of a halogenated xanthene induces an immune reaction that in turn kills further cancerous hematologic, non-tumorous cells.
The similarly useful halogenated xanthene compounds listed below and their pharmaceutically acceptable salts can have molecular weights that differ from each other by about a factor of three (See, Table 3, US Patent No. 7,390,688 at columns 15-16). It is preferred that an exact amount of other than RB
halogenated xanthene to be used is calculated based on published molecular weights for each such compound and that of RB.
A contemplated halogenated xanthene includes rose bengal (4,5,6,7-tetrachloro-2',4',5',7'-tetraiodo-fluorescein) that is particularly preferred, erythrosin B, phloxine B, 4,5,6,7-tetrabromo-2',4',5',7'-tetra-
-14-iodofluorescein, 21,4,5,6,7-pentachloro-4',5'77'-triiodofluorescein, 4,4',5,6,7-pentachloro-2',5'17'-triiodofluorescein, 21,4,5,6,7,7'-hexachloro-4',5'-diiodofluorescein, 4,4',5,5',6,7-hexachloro-2'17'-diiodofluorescein, 2',4,5,5',6,7-hexachloro-4',7'-diiodofluorescein, 4,5,6,7-tetrachloro-2',4',5'-triiodofluorescein, 4,5,6,7-tetrachloro-2'14',7'-triiodofluorescein, 4,5,6,7-tetrabromo-27,47,57-triiodofluorescein, and 4,5,6,7-tetrabromo-2'14',7'-triiodofluorescein. The reader is directed to Berge, J. Pharm. Sci. 1977 68(1):1-19 for lists of commonly used pharmaceutically acceptable acids and bases that form pharmaceutically acceptable salts with pharmaceutical compounds.
A C1-C4 alkyl ester of one of the above halogenated xanthene compounds can also be used, with the C2; i.e., ethyl ester, being preferred. Thus, in vitro studies using each of RB, ethyl-Red 3 (erythrosine ethyl ester; 2',4',5',7'-tetraiodo-fluorescein ethyl ester), 4,5,6,7-tetrabromo-2',4',5',7'-tetraiodofluorescein and ethyl-Pholoxine B
(4,5,6,7-tetrachloro-2',4',5',7'-tetrabromofluorescein ethyl ester) exhibited similar anti-tumor activities against CCL-142 renal adenocarcinoma.
A preferred form of rose bengal is rose bengal disodium that has the structural formula below:
A C1-C4 alkyl ester of one of the above halogenated xanthene compounds can also be used, with the C2; i.e., ethyl ester, being preferred. Thus, in vitro studies using each of RB, ethyl-Red 3 (erythrosine ethyl ester; 2',4',5',7'-tetraiodo-fluorescein ethyl ester), 4,5,6,7-tetrabromo-2',4',5',7'-tetraiodofluorescein and ethyl-Pholoxine B
(4,5,6,7-tetrachloro-2',4',5',7'-tetrabromofluorescein ethyl ester) exhibited similar anti-tumor activities against CCL-142 renal adenocarcinoma.
A preferred form of rose bengal is rose bengal disodium that has the structural formula below:
-15--CI
a a a COONa Na0 0!O.
Further details of the medicinal use a pharmaceutical composition containing an above-noted halogenated xanthine are described in U.S. Patents No. 5,998,597, No. 6,331,286, No. 6,493,570, No. 7,390,688, No.
7,648,695, No. 8,974,363, No. 9,107,887, No. 9,808,524, No. 9,839,688, No. 10,130,658 and No. 10,471,144, whose disclosures are incorporated by reference herein in their entireties.
A contemplated halogenated xanthene or its pharmaceutically acceptable salt is typically used dissolved or dispersed in an aqueous pharmaceutical composition. The halogenated xanthene is typically present at 0.1 to about 20 % (w/v) in an aqueous 0.9 %
saline pharmaceutical composition.
Because a contemplated pharmaceutical composition is typically intended for parenteral administration as by intravenous methods, such a composition should contain an electrolyte, and preferably have approximately physiological osmolality and pH value. A preferred concentration of singly charged electrolyte ions in a pharmaceutically acceptable aqueous medium is about 0.5 to about 1.5%
a a a COONa Na0 0!O.
Further details of the medicinal use a pharmaceutical composition containing an above-noted halogenated xanthine are described in U.S. Patents No. 5,998,597, No. 6,331,286, No. 6,493,570, No. 7,390,688, No.
7,648,695, No. 8,974,363, No. 9,107,887, No. 9,808,524, No. 9,839,688, No. 10,130,658 and No. 10,471,144, whose disclosures are incorporated by reference herein in their entireties.
A contemplated halogenated xanthene or its pharmaceutically acceptable salt is typically used dissolved or dispersed in an aqueous pharmaceutical composition. The halogenated xanthene is typically present at 0.1 to about 20 % (w/v) in an aqueous 0.9 %
saline pharmaceutical composition.
Because a contemplated pharmaceutical composition is typically intended for parenteral administration as by intravenous methods, such a composition should contain an electrolyte, and preferably have approximately physiological osmolality and pH value. A preferred concentration of singly charged electrolyte ions in a pharmaceutically acceptable aqueous medium is about 0.5 to about 1.5%
-16-(w/v), more preferably at about 0.8 to about 1.2%
(w/v), and most preferably at a concentration of about 0.9% (w/v). The about 0.9% (w/v) concentration is particularly preferred because it corresponds to an approximately isotonic aqueous solution. In a further preferred embodiment, the electrolyte in a chemoablative pharmaceutical composition is sodium chloride.
Electrolytes at such levels increase the osmolality of a pharmaceutically acceptable aqueous medium. Thus, as an alternative to specifying a range of electrolyte concentrations, osmolality can be used to characterize, in part, the electrolyte level of the composition. It is preferred that the osmolality of a composition be greater than about 100 mOsm/kg, more preferably that the osmolality of the composition be greater than about 250 mOsm/kg, and most preferably that it be about 300 to about 500 mOsm/kg.
It is preferred that the pH value of a pharmaceutically acceptable aqueous medium be about 4 to about 9, to yield maximum solubility of the halogenated xanthene in an aqueous vehicle and assure compatibility with biological tissue. A particularly preferred pH value is about 5 to about 8, and more preferably between about 6 to about 7.5. At these pH
values, the halogenated xanthenes typically remain in dibasic form, rather than the water-insoluble lactone that forms at low pH values.
The pH value of a pharmaceutically acceptable aqueous medium can be regulated or adjusted by any suitable means known to those of skill in the art. The composition can be buffered or the pH value adjusted by
(w/v), and most preferably at a concentration of about 0.9% (w/v). The about 0.9% (w/v) concentration is particularly preferred because it corresponds to an approximately isotonic aqueous solution. In a further preferred embodiment, the electrolyte in a chemoablative pharmaceutical composition is sodium chloride.
Electrolytes at such levels increase the osmolality of a pharmaceutically acceptable aqueous medium. Thus, as an alternative to specifying a range of electrolyte concentrations, osmolality can be used to characterize, in part, the electrolyte level of the composition. It is preferred that the osmolality of a composition be greater than about 100 mOsm/kg, more preferably that the osmolality of the composition be greater than about 250 mOsm/kg, and most preferably that it be about 300 to about 500 mOsm/kg.
It is preferred that the pH value of a pharmaceutically acceptable aqueous medium be about 4 to about 9, to yield maximum solubility of the halogenated xanthene in an aqueous vehicle and assure compatibility with biological tissue. A particularly preferred pH value is about 5 to about 8, and more preferably between about 6 to about 7.5. At these pH
values, the halogenated xanthenes typically remain in dibasic form, rather than the water-insoluble lactone that forms at low pH values.
The pH value of a pharmaceutically acceptable aqueous medium can be regulated or adjusted by any suitable means known to those of skill in the art. The composition can be buffered or the pH value adjusted by
-17-addition of acid or base or the like. As the halogenated xanthenes, or physiologically acceptable salts thereof, are weak acids, depending upon halogenated xanthene concentration and/or electrolyte concentration, the pH value of the composition may not require the use of a buffer and/or pH modifying reagent. It is especially preferred, however, that the composition not contain any buffer, permitting it to conform to the biological environment once administered.
In the present invention, the specific amount of halogenated xanthene in a pharmaceutical composition is not believed to be as important as was the case where the composition was injected intralesionally to a tumor because the object here is to ultimately provide a cytotoxic concentration of halogenated xanthene to the environment of the cancerous cells and in which those cancerous cells can be contacted with the halogenated xanthene. The data provided hereinafter indicate that an IC50 concentration of disodium rose bengal is about 50 to about 100 LIM for in vitro cultured leukemia cells.
The above results using in vitro cultured leukemia cells surprisingly provided data similar to those obtained in an in vitro cytotoxicity study of cultured SK-N-AS, SK-N-BE(2), IMR5, LAN1, SHEP, and SK-N-SH neuroblastoma cells, SK-N-MC neuroepithelioma cells, and normal primary, BJ, and WI38 fibroblasts reported by Swift et al., OncoTargets and Therapy 12:1-15 (2019). Those authors reported half maximal inhibitory concentration (IC50) values for PV-10-
In the present invention, the specific amount of halogenated xanthene in a pharmaceutical composition is not believed to be as important as was the case where the composition was injected intralesionally to a tumor because the object here is to ultimately provide a cytotoxic concentration of halogenated xanthene to the environment of the cancerous cells and in which those cancerous cells can be contacted with the halogenated xanthene. The data provided hereinafter indicate that an IC50 concentration of disodium rose bengal is about 50 to about 100 LIM for in vitro cultured leukemia cells.
The above results using in vitro cultured leukemia cells surprisingly provided data similar to those obtained in an in vitro cytotoxicity study of cultured SK-N-AS, SK-N-BE(2), IMR5, LAN1, SHEP, and SK-N-SH neuroblastoma cells, SK-N-MC neuroepithelioma cells, and normal primary, BJ, and WI38 fibroblasts reported by Swift et al., OncoTargets and Therapy 12:1-15 (2019). Those authors reported half maximal inhibitory concentration (IC50) values for PV-10-
-18-treated cells at 96 hours post treatment of 65-85 M for the neuroblastoma lines assayed and 49 RN for the neuroepithelioma line SK-N-MC. Those authors also examined toxicity toward human epithelial cells from three tissue sources and reported 1050 values of 93-143 M.
Presuming an IC50 value for leukemia cells of about 50 to about 100 M, a dose to kill about one-half of the leukemia cells in an adult would calculate to be about 50 to about 100 mg of RB/L, based on a molecular weight of 1018 9/mole for disodium RB. The classic IV
diagnostic use of RB was conducted giving 100 mg RB as a single IV dose. The standard adult blood volume is approximately 5 L. Thus, to achieve 100 mg/IL in the blood, an adult patient would need to receive approximately 500 mg of RE IV to achieve the IC50 value in the bloodstream. Intravenous (IV) dosing is a preferred method of administering a halogenated xanthene-containing composition to a mammalian subject in need.
In clinical studies of PV-10, RB has been tolerated at 1500 mg delivered IV. Due to the rapid clearance of RB from circulation (t1/2 about 30 minutes) an IV administration would require continuous infusion to maintain peak levels of RB in circulation (i.e., for up to several hours or more) during a single administration.
Administration of sufficient RB to achieve a circulating RB concentration at the IC50 level would not be toxic to all circulating leukemic cells (i.e.,
Presuming an IC50 value for leukemia cells of about 50 to about 100 M, a dose to kill about one-half of the leukemia cells in an adult would calculate to be about 50 to about 100 mg of RB/L, based on a molecular weight of 1018 9/mole for disodium RB. The classic IV
diagnostic use of RB was conducted giving 100 mg RB as a single IV dose. The standard adult blood volume is approximately 5 L. Thus, to achieve 100 mg/IL in the blood, an adult patient would need to receive approximately 500 mg of RE IV to achieve the IC50 value in the bloodstream. Intravenous (IV) dosing is a preferred method of administering a halogenated xanthene-containing composition to a mammalian subject in need.
In clinical studies of PV-10, RB has been tolerated at 1500 mg delivered IV. Due to the rapid clearance of RB from circulation (t1/2 about 30 minutes) an IV administration would require continuous infusion to maintain peak levels of RB in circulation (i.e., for up to several hours or more) during a single administration.
Administration of sufficient RB to achieve a circulating RB concentration at the IC50 level would not be toxic to all circulating leukemic cells (i.e.,
-19-only approximately half of the leukemic cells would be affected at the IC50). In some embodiments it can be preferred to administer RB in an amount that is a multiple of the IC50 level, up to approximately 1500 mg (i.e., 300 mM). Alternatively, however, it can be sufficient to kill only a fraction of tumor cells as a result of an individual administration.
The latter case can be preferable for avoiding a toxic reaction (i.e., tumor lysis syndrome) that can result from rapidly killed tumor cell burden.
Thus, Howard et al., N Engl L7 Med 364(19):1844-1854 (May 12, 2011) report that tumor lysis syndrome is the most common disease-related emergency encountered by physicians treating hematologic cancers.
A mammal having leukemia, lymphoma or myeloma in need of treatment (a mammalian subject) and to which a pharmaceutical composition containing a halogenated xanthene or its pharmaceutically acceptable salt can be administered can be a primate such as a human, an ape such as a chimpanzee or gorilla, a monkey such as a cynomolgus monkey or a macaque, a laboratory animal such as a rat, mouse or rabbit, a companion animal such as a dog, cat, horse, or a food animal such as a cow or steer, sheep, lamb, pig, goat, llama or the like.
As discussed in greater detail below, it can also be advantageous to kill only a portion of the leukemic cells during a single treatment to initiate a functional immune response against remaining cancer cell burden. A RB-initiated functional immune system response is believed to occur due at least in part from the action of RB-caused necrotic cell debris
The latter case can be preferable for avoiding a toxic reaction (i.e., tumor lysis syndrome) that can result from rapidly killed tumor cell burden.
Thus, Howard et al., N Engl L7 Med 364(19):1844-1854 (May 12, 2011) report that tumor lysis syndrome is the most common disease-related emergency encountered by physicians treating hematologic cancers.
A mammal having leukemia, lymphoma or myeloma in need of treatment (a mammalian subject) and to which a pharmaceutical composition containing a halogenated xanthene or its pharmaceutically acceptable salt can be administered can be a primate such as a human, an ape such as a chimpanzee or gorilla, a monkey such as a cynomolgus monkey or a macaque, a laboratory animal such as a rat, mouse or rabbit, a companion animal such as a dog, cat, horse, or a food animal such as a cow or steer, sheep, lamb, pig, goat, llama or the like.
As discussed in greater detail below, it can also be advantageous to kill only a portion of the leukemic cells during a single treatment to initiate a functional immune response against remaining cancer cell burden. A RB-initiated functional immune system response is believed to occur due at least in part from the action of RB-caused necrotic cell debris
-20-
21 circulating in the body induces an immune response that can prolong the effects of an initial administration of a halogenated xanthene such as RB.
An induced immune response can take a longer =
time to develop than the more immediate killing of the contacted cancerous cells. That delay in effect can occur because of the time needed for induction the appropriate B and T cell populations to attack and kill the leukemic cells as well as to induce long lasting memory T cells whose continued circulation can protect the patient from relapse.
In another aspect, an above pharmaceutical composition is used in conjunction with a second, differently-acting cytotoxic anticancer agent; i.e., a cytotoxic anticancer agent whose mechanism of action is different from that of the first cytotoxic agent, the halogenaed xanthene. As noted previously, the halogenated xanthenes localize in cancer cell lysosomes, increase the percentage of cells in Cl phase of the cell cycle and induces cell death by apoptosis [Swift et al., Oncotargets Ther, 12:1293-1307 (February 2019)].
A first type of second cytotoxic agent is a so-called 'small molecule". Such small molecules can be viewed as semi-specific cellular poisons in that they are generally more specific at killing cancer cells than non-cancerous cells. Almost all small molecule anticancer agents are less cancer-specific than a contemplated halogenated xanthene, and can result in causing sickness, baldness and other trauma to their recipient subjects that can lead to subjects leaving their treatment regimens.
These small molecules typically have molecular weights of about 200 to about 1000 Daltons (Da), and preferably about 250 to about 850 Da. This group of small molecules includes many of the previously noted molecules used to treating hematologic cancers such as calicheamicin (1368 Da), vinblastine (811 Da), vincristine (825 Da), monomethyl auristatin (718 Da), etoposide (589 Da), daunorubicin (528 Da), doxorubicin (544 Da), annamycin (640 Da), sorafenib (465 Da), clofarabine (304 Da), cisplatin (300 Da), irinotecan (587 Da) and cytabarine (243 Da). It is noted that many of these small molecules are used as their salts, prodrugs and/or esters, which consequently have greater molecular weights than those rounded values above.
A pharmaceutical composition having a second cytotoxic anti-cancer agent_ can also contain a small molecule as above-described that is conjugated to a lager molecule such as a protein, detergent and/or polymer such as poly(ethylene glycol) [PEG]. Such conjugations often minimize the toxicity of the small molecule and enhance situs of delivery as use of an antibody that binds to a cancerous cell. Additionally, a small molecule cytotoxic agent can be enveloped within a liposome, micelle or cyclodextrin molecule that can be adapted to bind specifically bind to cancerous cells and/or be endocytosed by the cancer cell. This group of encapsulated and conjugated small molecules' is included with the previously discussed small molecule group of second cytotoxic agents as their active cytotoxic agent is a small molecule.
An induced immune response can take a longer =
time to develop than the more immediate killing of the contacted cancerous cells. That delay in effect can occur because of the time needed for induction the appropriate B and T cell populations to attack and kill the leukemic cells as well as to induce long lasting memory T cells whose continued circulation can protect the patient from relapse.
In another aspect, an above pharmaceutical composition is used in conjunction with a second, differently-acting cytotoxic anticancer agent; i.e., a cytotoxic anticancer agent whose mechanism of action is different from that of the first cytotoxic agent, the halogenaed xanthene. As noted previously, the halogenated xanthenes localize in cancer cell lysosomes, increase the percentage of cells in Cl phase of the cell cycle and induces cell death by apoptosis [Swift et al., Oncotargets Ther, 12:1293-1307 (February 2019)].
A first type of second cytotoxic agent is a so-called 'small molecule". Such small molecules can be viewed as semi-specific cellular poisons in that they are generally more specific at killing cancer cells than non-cancerous cells. Almost all small molecule anticancer agents are less cancer-specific than a contemplated halogenated xanthene, and can result in causing sickness, baldness and other trauma to their recipient subjects that can lead to subjects leaving their treatment regimens.
These small molecules typically have molecular weights of about 200 to about 1000 Daltons (Da), and preferably about 250 to about 850 Da. This group of small molecules includes many of the previously noted molecules used to treating hematologic cancers such as calicheamicin (1368 Da), vinblastine (811 Da), vincristine (825 Da), monomethyl auristatin (718 Da), etoposide (589 Da), daunorubicin (528 Da), doxorubicin (544 Da), annamycin (640 Da), sorafenib (465 Da), clofarabine (304 Da), cisplatin (300 Da), irinotecan (587 Da) and cytabarine (243 Da). It is noted that many of these small molecules are used as their salts, prodrugs and/or esters, which consequently have greater molecular weights than those rounded values above.
A pharmaceutical composition having a second cytotoxic anti-cancer agent_ can also contain a small molecule as above-described that is conjugated to a lager molecule such as a protein, detergent and/or polymer such as poly(ethylene glycol) [PEG]. Such conjugations often minimize the toxicity of the small molecule and enhance situs of delivery as use of an antibody that binds to a cancerous cell. Additionally, a small molecule cytotoxic agent can be enveloped within a liposome, micelle or cyclodextrin molecule that can be adapted to bind specifically bind to cancerous cells and/or be endocytosed by the cancer cell. This group of encapsulated and conjugated small molecules' is included with the previously discussed small molecule group of second cytotoxic agents as their active cytotoxic agent is a small molecule.
-22-Illustrative of such second cytotoxic agents are liposomal daunorubicin, liposomal annamycin, sphingosomal vincristine, liposomal cytarabine, a ealicheamicin-conjugated CD33 antibody called gemtuzumab ozogamicin and a chimer of CD30 antibody and monomethyl auristatin E called brentuximab vedotin.
Briefly, liposomes are generally spherically-shaped artificial vesicles typically prepared from cholesterol and phospholipid molecules that constitute one or two bilayers and encapsulate the small molecule second cytotoxic agent to assist delivery. See, Akbarzadeh et al., Nanoscale Res Lett, 8:102 (2013).
Calicheamicin, is a high molecular weight small molecule (1368 Da), and contains four linked saccharides interrupted by a benzothioate S-ester linkage as well as an ene-diyne group that cleaves DNA
sequences. Calicheamicin is too toxic: Lo be used alone, LD50 in nude mice of 320 lig/kg [DiJoseph et al., Blood 103:1807-1814 (2004)1. Similarly, monomethyl auristatin exhibits general (broad range), high toxicity [IC50 < 1 nM for several cancer cell lines;
ApexBio Technology Product Catalog (2013)] that is mediated by linkage to an antibody against CD30 (a TNF
receptor-family member that is a cell membrane protein and cancer marker) was reported useful against large cell lymphoma and Hodgkin's disease [Francisco et al., Blood 102:1458-1465 (2003)], whereas linkage to an anti-CD79b monoclonal provided an advantage in treating three xenograft models of NHL [Dornan et al., Blood 114:2721-2729 (2009)1.
Briefly, liposomes are generally spherically-shaped artificial vesicles typically prepared from cholesterol and phospholipid molecules that constitute one or two bilayers and encapsulate the small molecule second cytotoxic agent to assist delivery. See, Akbarzadeh et al., Nanoscale Res Lett, 8:102 (2013).
Calicheamicin, is a high molecular weight small molecule (1368 Da), and contains four linked saccharides interrupted by a benzothioate S-ester linkage as well as an ene-diyne group that cleaves DNA
sequences. Calicheamicin is too toxic: Lo be used alone, LD50 in nude mice of 320 lig/kg [DiJoseph et al., Blood 103:1807-1814 (2004)1. Similarly, monomethyl auristatin exhibits general (broad range), high toxicity [IC50 < 1 nM for several cancer cell lines;
ApexBio Technology Product Catalog (2013)] that is mediated by linkage to an antibody against CD30 (a TNF
receptor-family member that is a cell membrane protein and cancer marker) was reported useful against large cell lymphoma and Hodgkin's disease [Francisco et al., Blood 102:1458-1465 (2003)], whereas linkage to an anti-CD79b monoclonal provided an advantage in treating three xenograft models of NHL [Dornan et al., Blood 114:2721-2729 (2009)1.
-23-A systemic anti-cancer medication that is a small molecule (non-proteinaceous, less than about 1000 grams/mole) or a larger proteinaceous molecule, is administered to the subject mammal to be treated such that the medication spreads throughout the subject's body as compared to the localized administration that occurs with an intralesional administration of a halogenated xanthene. Intravenous administration is a preferred method to achieve that spread of medication.
Illustrative small molecule anti-cancer medications include doxorubicin, etoposide, vincristine, cisplatin, irinotecan and cytarabine that were used herein, whereas an exemplary proteinaceous molecule is egasparaginase. Of those medications, doxorubicin, etoposide and vincristine appeared to synergize with treatment with a sub-lethal dose of PV-10, and are preferred.
It is to be understood that administration of any of the second cancer cytotoxic agents discussed herein can be undertaken multiple times. Such multiple administrations are within the purview of the treating physician, and can be made in conjunction with an administration of a first cancer cytotoxic agent or can be carried out separately.
A useful effective dosage of a small molecule systemic anti-cancer medication is the dosage set out in the labeling information of a FDA-, national- or international agency-approved medication. Typically, monotherapy dose schedules are set by determining the maximum tolerated dose (MTD) in early-stage clinical trials. The MTD (or a close variation thereon) is then promulgated to later-stage clinical trials for
Illustrative small molecule anti-cancer medications include doxorubicin, etoposide, vincristine, cisplatin, irinotecan and cytarabine that were used herein, whereas an exemplary proteinaceous molecule is egasparaginase. Of those medications, doxorubicin, etoposide and vincristine appeared to synergize with treatment with a sub-lethal dose of PV-10, and are preferred.
It is to be understood that administration of any of the second cancer cytotoxic agents discussed herein can be undertaken multiple times. Such multiple administrations are within the purview of the treating physician, and can be made in conjunction with an administration of a first cancer cytotoxic agent or can be carried out separately.
A useful effective dosage of a small molecule systemic anti-cancer medication is the dosage set out in the labeling information of a FDA-, national- or international agency-approved medication. Typically, monotherapy dose schedules are set by determining the maximum tolerated dose (MTD) in early-stage clinical trials. The MTD (or a close variation thereon) is then promulgated to later-stage clinical trials for
-24--assessment efficacy and more detailed assessment of safety. These MTDs frequently become the established therapeutic dose upon completion of clinical testing.
However, because the small molecule, systemic anti-cancer medication is contemplated for use with PV-10, a MTD is the maximal amount that would normally be used, and that amount is to be titrated downward following usual procedures.
Exemplary dosing schedules for a number of systemic anti-cancer medications that can be combined with halogenated xanthene therapy in the present invention are provided in Table A, below. It is noted that several of the medications listed below are "small molecules" as defined above, whereas others are large, proteinaceous molecules such as antibodies. They are nonetheless administered systemically.
Table A
Exemplary systemic immunomodulatory or targeted anticancer agents Systemic Agent Typical Dose Schedule adalimumab 80 mg initial dose followed in 1 week by 40 mg every other week SQ
brodalumab 210 mg subcutaneously (SC) at Weeks 0, 1, and 2, then 210 mg SC q2wk certolizumab pegol 400 mg initially and at weeks 2 and 4 followed by 200 mg every other week or 400 mg Q4 weeks maintenance SQ
etanercept 50 mg twice weekly for 3 months followed by 50 mg once weekly SQ
golimumab 50 mg once a month SQ
guselkumab 100 mg subcutaneous injection once every 8 weeks, after starter doses at weeks 0 and 4
However, because the small molecule, systemic anti-cancer medication is contemplated for use with PV-10, a MTD is the maximal amount that would normally be used, and that amount is to be titrated downward following usual procedures.
Exemplary dosing schedules for a number of systemic anti-cancer medications that can be combined with halogenated xanthene therapy in the present invention are provided in Table A, below. It is noted that several of the medications listed below are "small molecules" as defined above, whereas others are large, proteinaceous molecules such as antibodies. They are nonetheless administered systemically.
Table A
Exemplary systemic immunomodulatory or targeted anticancer agents Systemic Agent Typical Dose Schedule adalimumab 80 mg initial dose followed in 1 week by 40 mg every other week SQ
brodalumab 210 mg subcutaneously (SC) at Weeks 0, 1, and 2, then 210 mg SC q2wk certolizumab pegol 400 mg initially and at weeks 2 and 4 followed by 200 mg every other week or 400 mg Q4 weeks maintenance SQ
etanercept 50 mg twice weekly for 3 months followed by 50 mg once weekly SQ
golimumab 50 mg once a month SQ
guselkumab 100 mg subcutaneous injection once every 8 weeks, after starter doses at weeks 0 and 4
-25-infliximab 5 mg/kg given as an IV induction regimen at 0, 2, and 6 weeks followed by a maintenance regimen of 5 mg/kg every 8 weeks thereafter ixekizumab 160 mg initial dose followed Q2 weeks with 80 mg until week 12 then 80 mg QA weeks SQ
sarilumab 200 mg every 2 weeks as a subcutaneous injection secukinumab 300 mg every week for 4 weeks then 300 mg every 4 weeks SQ
ustekinumab Less than 100 kg: 45 mg initially, week 4 followed by 45 mg every 12 weeks SQ
More than 100 kg: 90 mg initially, week 4 followed by 90 mg every 12 weeks SO
apremilast Titrated dose over 5 days to work up to 30 mg twice daily PO
methotrexate Weekly single oral, IM or TV 10 to 25 mg per week or divided 2.5 mg dose at 12 hour intervals for three doses cyclosporine Initial dose 2.5 mg/kg/day taken twice daily as divided (BID); dose titrated up to 4 mg/kg/day BID if response and laboratory abnormalities don't ensue.
azathioprine Used off label for skin diseases, 1.0 mg/kg oral or IV as a single dose or twice a day, dose maximum is 2.5 mg/kg/day.
Because of additive or synergistic effects, the combination therapies and method of treatment of the present invention generally permit use of the systemic agent at a level at or below the typical dose
sarilumab 200 mg every 2 weeks as a subcutaneous injection secukinumab 300 mg every week for 4 weeks then 300 mg every 4 weeks SQ
ustekinumab Less than 100 kg: 45 mg initially, week 4 followed by 45 mg every 12 weeks SQ
More than 100 kg: 90 mg initially, week 4 followed by 90 mg every 12 weeks SO
apremilast Titrated dose over 5 days to work up to 30 mg twice daily PO
methotrexate Weekly single oral, IM or TV 10 to 25 mg per week or divided 2.5 mg dose at 12 hour intervals for three doses cyclosporine Initial dose 2.5 mg/kg/day taken twice daily as divided (BID); dose titrated up to 4 mg/kg/day BID if response and laboratory abnormalities don't ensue.
azathioprine Used off label for skin diseases, 1.0 mg/kg oral or IV as a single dose or twice a day, dose maximum is 2.5 mg/kg/day.
Because of additive or synergistic effects, the combination therapies and method of treatment of the present invention generally permit use of the systemic agent at a level at or below the typical dose
-26-schedule for the systemic agent, such as those described in Table AL, when used with an IV
administration therapy, such as that described below.
However, the dosing schedules provided in Table A
provide a useful guide for beginning treatment from which dosages can be titrated to lessened amounts as seen appropriate by the physician caring for a given patient.
It is noted that a halogenated xanthene and a second cytotoxic anti-cancer agent need not be administered together nor by the same means of administration. Thus, a pill or capsule can be used to administer the second cytotoxic anti-cancer agent, while the halogenated xanthene is administered IV.
Those skilled in the art are well aware of the various methods of administering anticancer agents.
A second type of second cytotoxic agent useful for combination treatment with a halogenated xanthene such as that present in PV-10 is an immune checkpoint inhibitor, that can also be viewed as a special systemic anti-cancer medication. An immune checkpoint inhibitor is a drug that binds to and blocks certain checkpoint proteins made by immune system cells such as T cells and some cancer cells. When not blocked, those proteins inhibit immune responses, helping keep immune responses in check and keeping T
cells from killing cancer cells. Blocking those immune checkpoint proteins releases the "brakes" on the immune system permitting T cells to become activated and kill cancer cells.
A useful immune checkpoint inhibitor is preferably a human or humanized monoclonal antibody or
administration therapy, such as that described below.
However, the dosing schedules provided in Table A
provide a useful guide for beginning treatment from which dosages can be titrated to lessened amounts as seen appropriate by the physician caring for a given patient.
It is noted that a halogenated xanthene and a second cytotoxic anti-cancer agent need not be administered together nor by the same means of administration. Thus, a pill or capsule can be used to administer the second cytotoxic anti-cancer agent, while the halogenated xanthene is administered IV.
Those skilled in the art are well aware of the various methods of administering anticancer agents.
A second type of second cytotoxic agent useful for combination treatment with a halogenated xanthene such as that present in PV-10 is an immune checkpoint inhibitor, that can also be viewed as a special systemic anti-cancer medication. An immune checkpoint inhibitor is a drug that binds to and blocks certain checkpoint proteins made by immune system cells such as T cells and some cancer cells. When not blocked, those proteins inhibit immune responses, helping keep immune responses in check and keeping T
cells from killing cancer cells. Blocking those immune checkpoint proteins releases the "brakes" on the immune system permitting T cells to become activated and kill cancer cells.
A useful immune checkpoint inhibitor is preferably a human or humanized monoclonal antibody or
-27-binding portion thereof whose administration blocks the action of those certain proteins, thereby permitting the immune system to recognize the cancer cells as foreign and assist in eliminating those cancer cells from the body. Illustrative immune checkpoint inhibitors include the anti-CTLA-4 (cytotoxic T
lymphocyte-associated antigen 4) monoclonal antibodies ipilimumab and tremelimumab that are designed to counter down-regulation of the immune system by blocking CTLA-4 activity and thus augment T-cell response against cancer. Similarly, monoclonal antibodies such as pidilizumab, nivolumab, lambrolizumab and pembrolizumab bind to PD-1 (programmed death 1) receptor to counter down-regulation of the immune system and augment T-cell responses to cancerous cells. Three antibodies that target the immune checkpoint protein ligand (PD-L1) for the PD-1 receptor (PD-L1) are atezolizumab, avelumab and durvalumab. Initial work with antibodies to the PD-1 receptor ligands, PD-Li and PD-L2, such as BMS-936559 and MEDI4736 (durvalumab) to PD-L1, also indicate inhibition of down-regulation of the immune system and an augmented T-cell response against cancer.
Another group of antibodies with checkpoint inhibitor-like activity immunoreact with the cell surface receptor 0X40 (C0134) to stimulate proliferation of memory and effector T-lymphocytes, and thereby stimulate a T-cell-mediated immune response against cancerous cells. Exemplary such humanized anti-0X40 monoclonal antibodies include those presently referred to in the literature as gsk3174998 (IgG1),
lymphocyte-associated antigen 4) monoclonal antibodies ipilimumab and tremelimumab that are designed to counter down-regulation of the immune system by blocking CTLA-4 activity and thus augment T-cell response against cancer. Similarly, monoclonal antibodies such as pidilizumab, nivolumab, lambrolizumab and pembrolizumab bind to PD-1 (programmed death 1) receptor to counter down-regulation of the immune system and augment T-cell responses to cancerous cells. Three antibodies that target the immune checkpoint protein ligand (PD-L1) for the PD-1 receptor (PD-L1) are atezolizumab, avelumab and durvalumab. Initial work with antibodies to the PD-1 receptor ligands, PD-Li and PD-L2, such as BMS-936559 and MEDI4736 (durvalumab) to PD-L1, also indicate inhibition of down-regulation of the immune system and an augmented T-cell response against cancer.
Another group of antibodies with checkpoint inhibitor-like activity immunoreact with the cell surface receptor 0X40 (C0134) to stimulate proliferation of memory and effector T-lymphocytes, and thereby stimulate a T-cell-mediated immune response against cancerous cells. Exemplary such humanized anti-0X40 monoclonal antibodies include those presently referred to in the literature as gsk3174998 (IgG1),
-28-pogalizumab (M0XR0916), ME1J10562 and the human anti-0X40 IgG2 antibody designated PF-04518600 (PF-8600).
Intact monoclonal antibodies, as well their paratope-containing portions (binding site-containing portions) such as Fab, Fab', F(ab1)2 and Fv regions, as well as single-stranded peptide binding sequences can be useful as immune checkpoint protein inhibitors.
Intact checkpoint inhibiting monoclonal antibodies have half-lives in a human body of about one to three weeks [e.g., Yervoy (ipilimumab) terminal tin = 15.4 days;
package insert 12/2013; Keytruda0 (pembrolizumab) terminal t1/2 = 23 days; package insert 03/2017], and single-stranded oligo or polypeptides tend to have shorter half-lives in viva.
Because of the relatively short half-lives of the small molecule second cytotoxic anticancer agents and a halogenated xanthene medicament, both medicaments can be administered in a single composition or in separate compositions. If administered separately, it is preferred to administer both types of anticancer agent within minutes to about 3 hours of each other.
More preferably, both are administered within less than one hour of the other.
As used herein, "administration" is used to mean the beginning of a treatment regimen. Thus, swallowing a tablet or other per os dosage form is the beginning of a treatment regimen, as is the time at which an IV flow is begun. When both first and second cytotoxic anticancer agents are present together in the same, single composition, administration begins when that unitary composition enters the subject's body.
Intact monoclonal antibodies, as well their paratope-containing portions (binding site-containing portions) such as Fab, Fab', F(ab1)2 and Fv regions, as well as single-stranded peptide binding sequences can be useful as immune checkpoint protein inhibitors.
Intact checkpoint inhibiting monoclonal antibodies have half-lives in a human body of about one to three weeks [e.g., Yervoy (ipilimumab) terminal tin = 15.4 days;
package insert 12/2013; Keytruda0 (pembrolizumab) terminal t1/2 = 23 days; package insert 03/2017], and single-stranded oligo or polypeptides tend to have shorter half-lives in viva.
Because of the relatively short half-lives of the small molecule second cytotoxic anticancer agents and a halogenated xanthene medicament, both medicaments can be administered in a single composition or in separate compositions. If administered separately, it is preferred to administer both types of anticancer agent within minutes to about 3 hours of each other.
More preferably, both are administered within less than one hour of the other.
As used herein, "administration" is used to mean the beginning of a treatment regimen. Thus, swallowing a tablet or other per os dosage form is the beginning of a treatment regimen, as is the time at which an IV flow is begun. When both first and second cytotoxic anticancer agents are present together in the same, single composition, administration begins when that unitary composition enters the subject's body.
-29--Where the second cytotoxic anticancer agent is an immune checkpoint inhibitor such as a monoclonal antibody, the halogenated xanthene and the second cytotoxic anticancer agent immune checkpoint inhibitor can be administered together or one before the other, with the second cytotoxic anticancer agent immune checkpoint inhibitor being administered up to about one month prior to the halogenated xanthene. Preferably, the two cytotoxic anticancer agents are administered together or with the second cytotoxic anticancer agent immune checkpoint inhibitor being administered within a few days after the halogenated xanthene. A second cytotoxic anticancer agent immune checkpoint inhibitor can also be administered about one month after the halogenated xanthene.
Results Results of preliminary in vitro cell culture viability assays were carried out on a panel of eleven commercially available leukemia cell lines derived from patients with either primary or relapsed pediatric leukemia that were treated with PV-10 (Table 1) and two primary leukemia samples (Table 2).
Cell viability was measured by alamar blue assay, 96 hours post-treatment. PV-10 decreased cancer cell viability in a concentration and time dependent manner in the eleven pediatric leukemia cell lines (mean IC50 92.8 pM), and three primary leukemia samples (mean IC50 122.5 pM) examined.
The results show that PV-10 is cytotoxic to leukemia cell lines with a mean IC50 value of 92.8 pM (Table 1, below) and is cytotoxic to two primary leukemia samples with a mean IC50 value of 122.5 pM (Table 2, below).
Results Results of preliminary in vitro cell culture viability assays were carried out on a panel of eleven commercially available leukemia cell lines derived from patients with either primary or relapsed pediatric leukemia that were treated with PV-10 (Table 1) and two primary leukemia samples (Table 2).
Cell viability was measured by alamar blue assay, 96 hours post-treatment. PV-10 decreased cancer cell viability in a concentration and time dependent manner in the eleven pediatric leukemia cell lines (mean IC50 92.8 pM), and three primary leukemia samples (mean IC50 122.5 pM) examined.
The results show that PV-10 is cytotoxic to leukemia cell lines with a mean IC50 value of 92.8 pM (Table 1, below) and is cytotoxic to two primary leukemia samples with a mean IC50 value of 122.5 pM (Table 2, below).
-30-Table 1*
Cell Line Cell Type PV-10 IC50 PM
KOPM8 Infant acute T-ALL
lymphoblastic leukemiatib=20 SEM B-ALL
CCRF-SB B-ALL
Kasumil AML
Biphenotypic 68 Molm13 AML
Molt4 T-ALL
Molt3 T-ALL
Mean 92.8 *Half maximal inhibitory concentration (IC50) values for pediatric leukemia cell lines treated with PV-10 for 96 hours.
Table 2**
Cell Type T-ALL
Infant AML
Mean 122.5 **Half maximal inhibitory concentration (IC50) values for primary pediatric leukemia samples treated with PV-10 for 96 hours.
Observation of four different leukemia cell lines (Molm-13, MV4-11, SEM, TIB-202) by phase-contrast and time-lapse video microscopy indicated that PV-10 was cytotoxic and not cytostatic to the cancerous cells. Quantification of dead cells from time-lapse video microscopy experiments showed that PV-10 was cytotoxio in a cell line in a concentration-dependent manner.
Cell Line Cell Type PV-10 IC50 PM
KOPM8 Infant acute T-ALL
lymphoblastic leukemiatib=20 SEM B-ALL
CCRF-SB B-ALL
Kasumil AML
Biphenotypic 68 Molm13 AML
Molt4 T-ALL
Molt3 T-ALL
Mean 92.8 *Half maximal inhibitory concentration (IC50) values for pediatric leukemia cell lines treated with PV-10 for 96 hours.
Table 2**
Cell Type T-ALL
Infant AML
Mean 122.5 **Half maximal inhibitory concentration (IC50) values for primary pediatric leukemia samples treated with PV-10 for 96 hours.
Observation of four different leukemia cell lines (Molm-13, MV4-11, SEM, TIB-202) by phase-contrast and time-lapse video microscopy indicated that PV-10 was cytotoxic and not cytostatic to the cancerous cells. Quantification of dead cells from time-lapse video microscopy experiments showed that PV-10 was cytotoxio in a cell line in a concentration-dependent manner.
-31-At 24 hours post-treatment with 100 pM PV-10, 88% of MV4-11 cells, 69% of Molm-13 cells, 27% of TIB-202 cells and 25% of SEM cells had undergone cell death. When the concentration of PV-10 was increased to 200 pM, 100% of MV4-11 and Molm13 cells, 94% of SEM
cells and 60% of TIB-202 cells had undergone cell death, 24 hours after treatment.
Additionally, observation by time-lapse video microscopy suggested that cells were dying by apoptosis, as treatment with PV-10 led to cell shrinkage. Induction of apoptosis by PV-10 was confirmed by dose and time dependent PARE cleavage, detected by western blot. [Swift et al., Blood, 132, No. Sqppl II 5207 (November 21, 2018).]
These studies provide first evidence in pre-clinical data for the activity and mechanisms of action of PV-10 in pediatric leukemia. These data provide the rationale for additional studies and the formulation of an early-phase clinical trial for patients with relapsed and refractory pediatric leukemia.
Method's:
A panel of eleven cell lines derived from patients with either primary or relapsed pediatric leukemia (CEM-C1, CCRF-SB, Kasumi-1, KOPN8, Molm-13, Molt-3, Molt-4, MV4-11, SEM, SUP-315 and TIB-202) and cells from three primary leukemia patient specimens (T-ALL, AML, Infant AML) were treated with increasing concentrations of PV-10 and cell viability was measured by alamar blue assay, 96 hours post-treatment. Target modulation and induction of cell death pathways were
cells and 60% of TIB-202 cells had undergone cell death, 24 hours after treatment.
Additionally, observation by time-lapse video microscopy suggested that cells were dying by apoptosis, as treatment with PV-10 led to cell shrinkage. Induction of apoptosis by PV-10 was confirmed by dose and time dependent PARE cleavage, detected by western blot. [Swift et al., Blood, 132, No. Sqppl II 5207 (November 21, 2018).]
These studies provide first evidence in pre-clinical data for the activity and mechanisms of action of PV-10 in pediatric leukemia. These data provide the rationale for additional studies and the formulation of an early-phase clinical trial for patients with relapsed and refractory pediatric leukemia.
Method's:
A panel of eleven cell lines derived from patients with either primary or relapsed pediatric leukemia (CEM-C1, CCRF-SB, Kasumi-1, KOPN8, Molm-13, Molt-3, Molt-4, MV4-11, SEM, SUP-315 and TIB-202) and cells from three primary leukemia patient specimens (T-ALL, AML, Infant AML) were treated with increasing concentrations of PV-10 and cell viability was measured by alamar blue assay, 96 hours post-treatment. Target modulation and induction of cell death pathways were
-32-investigated by western blot, phase-contrast microscopy and time-lapse video microscopy.
Analysis of cell cycle alterations and induction of apoptosis were measured by flow eytometry.
Combination studies are performed to identify anti-cancer agents that are synergistic with PV-10 and animal models of pediatric leukemia used to identify the activity of PV-10 against pediatric leukemia in vivo.
Previous Studies Previous studies have shown that the halogenated xanthene compounds discussed previously provide results against cancerous tumor cells that are similar to those achieved with RB.
Previous Procedures A. 1 x 104 cells/mL were injected subcutaneously into BALB/c nude mice. 2-3 Weeks were required for tumors to grow to treatable volume.
B. 20 L to 40 L of halogenated xanthene solutions (0.01, 0.001 or 0.1% w/v) was injected until tumor was completely infiltrated. One could see the tumor begin to turn red as the agent was injected.
C. Twenty-four hours after injection, the tumors were illuminated by laser. Laser: Coherent, Verdi 5W, 532nm CW laser, 200mW/cm2, 100J/ cm2, 4cm2 treatment zone.
D. Confirmation of Specificity by Bioassay:
Color retention of the agent in the tumor 24 hours after intratumoral injection was determined by production of photodynamic damage confined to the tumor
Analysis of cell cycle alterations and induction of apoptosis were measured by flow eytometry.
Combination studies are performed to identify anti-cancer agents that are synergistic with PV-10 and animal models of pediatric leukemia used to identify the activity of PV-10 against pediatric leukemia in vivo.
Previous Studies Previous studies have shown that the halogenated xanthene compounds discussed previously provide results against cancerous tumor cells that are similar to those achieved with RB.
Previous Procedures A. 1 x 104 cells/mL were injected subcutaneously into BALB/c nude mice. 2-3 Weeks were required for tumors to grow to treatable volume.
B. 20 L to 40 L of halogenated xanthene solutions (0.01, 0.001 or 0.1% w/v) was injected until tumor was completely infiltrated. One could see the tumor begin to turn red as the agent was injected.
C. Twenty-four hours after injection, the tumors were illuminated by laser. Laser: Coherent, Verdi 5W, 532nm CW laser, 200mW/cm2, 100J/ cm2, 4cm2 treatment zone.
D. Confirmation of Specificity by Bioassay:
Color retention of the agent in the tumor 24 hours after intratumoral injection was determined by production of photodynamic damage confined to the tumor
-33-as evidenced by eschar and volume reduction after illumination. Failure of tumor to reoccur at the primary site was recorded.
E. Confirmation of Specificity by Fluorescence: Retention of compounds in the tumors 24 hours after intratumoral delivery was confirmed by visually observing fluorescence of the halogenated xanthene agent in the tumor excited by the CW laser.
The 532 nm exciting wavelength was removed using a Melles Griot filter Part No. 03 FIM 008. Fluorescence of the compounds was recorded using an Olympus digital camera (Model 0-300-L).
Results I Compound I
Results Amount (paw %) Rose Bengal 0.01 24 hours post illumination 3/3 mice eschar production and full tumor reduction days post illumination 3/3 mice reoccurrence of tumor 0.001 24 hours post illumination 3/5 eschar production (1/5 partial) 5 days post illumination 3/3 mice reoccurrence of tumor Ethyl Red 0.1 24 hours post illumination 2/2 mice eschar production and full tumor reduction 3 days post illumination 3/3 mice reoccurrence of tumor Red 3 0.1 24 hours post illumination 0/3 no eschar and no tumor reduction PH-12*
0.01 24 hours post illumination 3/3 mice eschar production and full tumor reduction 7 days post illumination 0/3 mice reoccurrence of tumor Ethyl-PB**
0.01 24 hours post illumination 2/2 mice eschar production and full tumor reduction 5 days post illumination 2/2 mice reoccurrence of tumor
E. Confirmation of Specificity by Fluorescence: Retention of compounds in the tumors 24 hours after intratumoral delivery was confirmed by visually observing fluorescence of the halogenated xanthene agent in the tumor excited by the CW laser.
The 532 nm exciting wavelength was removed using a Melles Griot filter Part No. 03 FIM 008. Fluorescence of the compounds was recorded using an Olympus digital camera (Model 0-300-L).
Results I Compound I
Results Amount (paw %) Rose Bengal 0.01 24 hours post illumination 3/3 mice eschar production and full tumor reduction days post illumination 3/3 mice reoccurrence of tumor 0.001 24 hours post illumination 3/5 eschar production (1/5 partial) 5 days post illumination 3/3 mice reoccurrence of tumor Ethyl Red 0.1 24 hours post illumination 2/2 mice eschar production and full tumor reduction 3 days post illumination 3/3 mice reoccurrence of tumor Red 3 0.1 24 hours post illumination 0/3 no eschar and no tumor reduction PH-12*
0.01 24 hours post illumination 3/3 mice eschar production and full tumor reduction 7 days post illumination 0/3 mice reoccurrence of tumor Ethyl-PB**
0.01 24 hours post illumination 2/2 mice eschar production and full tumor reduction 5 days post illumination 2/2 mice reoccurrence of tumor
-34-*PH-12 = 2',4',5',7f-tetrabromo-4,5,6,7-tetraiodoerythrosin prepared and supplied by Molecular Probes Inc.
**Phloxine B the unesterified parent compound of Ethyl-phloxine B has been examined previously and is not retained in tumors.
Each of the patents, patent applications and articles cited herein is incorporated by reference.
The articles "a" and "an" are used herein to refer to one or to more than one (i.e., to at least one) of the grammatical object of the article. Each of the patents, patent applications and articles cited herein is incorporated by reference.
The foregoing description and the examples are intended as illustrative and are not to be taken as limiting. Still other variations within the spirit and scope of this invention are possible and will readily present themselves to those skilled in the art.
**Phloxine B the unesterified parent compound of Ethyl-phloxine B has been examined previously and is not retained in tumors.
Each of the patents, patent applications and articles cited herein is incorporated by reference.
The articles "a" and "an" are used herein to refer to one or to more than one (i.e., to at least one) of the grammatical object of the article. Each of the patents, patent applications and articles cited herein is incorporated by reference.
The foregoing description and the examples are intended as illustrative and are not to be taken as limiting. Still other variations within the spirit and scope of this invention are possible and will readily present themselves to those skilled in the art.
-35-
Claims (39)
1. A method of treating a mammalian subject having hematologic, non-tumorous cancer cells comprising the steps of:
(A) administering a therapeutically effective amount of a halogenated xanthene, a pharmaceutically acceptable salt or a 01-04 alkyl ester thereof as a first cancer cytotoxic agent dissolved or dispersed in a pharmaceutically acceptable aqueous medium to a mammalian subject having hematologic, non-tumorous cancer cells; and (B) maintaining said mammalian subject for a period of time sufficient to induce death of hematologic, non-tumorous cancer cells.
(A) administering a therapeutically effective amount of a halogenated xanthene, a pharmaceutically acceptable salt or a 01-04 alkyl ester thereof as a first cancer cytotoxic agent dissolved or dispersed in a pharmaceutically acceptable aqueous medium to a mammalian subject having hematologic, non-tumorous cancer cells; and (B) maintaining said mammalian subject for a period of time sufficient to induce death of hematologic, non-tumorous cancer cells.
2.
The method according to claim 1, wherein said steps are repeated.
The method according to claim 1, wherein said steps are repeated.
3. The method according to claim 1, wherein the cancer of said hematologic, non-tumorous cancer cells is leukemia, lymphoma or myeloma.
4. The method according to claim 3, wherein the leukemia, lymphoma or myeloma is selected from the group consisting of acute B-cell or T-cell lymphoblastic leukemia, acute myeloid leukemia, non-Hodgkin's lymphoma, and Hodgkin's lymphoma.
5. The method according to claim 1, wherein said contacting is carried out in vivo in said mammalian subject.
6. The method according to claim 5, wherein said mammalian subject is selected from the group consisting of a human, an ape, a monkey, a laboratory animal, a companion animal and a food animal.
7. The method according to claim 1, wherein said first cancer cytotoxic agent halogenated xanthene, pharmaceutically acceptable salt or C1-04 alkyl ester thereof is rose bengal, a pharmaceutically acceptable salt or C1-04 alkyl ester thereof.
8. The method according to claim 7, wherein said rose bengal, a pharmaceutically acceptable salt or C1-C4 alkyl ester thereof is rose bengal disodium salt.
9. The method according to claim 1, wherein said pharmaceutically acceptable aqueous medium is an approximately isotonic aqueous solution.
10. The method according to claim 1, wherein said administration of step (A) is carried out in conjunction with administration to said mammalian subject of a second therapeutically effective amount of a second, differently-acting cancer cytotoxic agent dissolved or dispersed in a pharmaceutically acceptable medium.
11. The method according to claim 10, wherein said second cancer cytotoxic agent is dissolved or dispersed in a pharmaceutically acceptable solid medium.
12. The method according to claim 11, wherein the pharmaceutically acceptable solid medium containing the second cancer cytotoxic agent is administered per os.
13. The method according to claim 10, wherein second cancer cytotoxic agent is a small molecule having a molecular weight of about 200 to about 1000 Da.
14. The method according to claim 10, wherein said small molecule exhibits synergy with said first cancer cytotoxic agent.
15. The method according to claim 10, wherein said second cancer cytotoxic agent is dissolved or dispersed in a pharmaceutically acceptable aqueous medium.
16. The method according to claim 15, wherein the pharmaceutically acceptable aqueous medium containing the second cancer cytotoxic agent is administered intravenously.
17. The method according to claim 16, wherein the second cancer cytotoxic agent comprises intact monoclonal antibodies or paratope-containing portions thereof.
18. The method according to claim 17, wherein said intact monoclonal antibodies or paratope-containing portions thereof are immune checkpoint protein inhibitors.
19. The method according to claim 18, wherein said immune checkpoint protein inhibitors bind to one or more proteinaceous materials selected from one or more of the group consisting of CTLA-4, PD-11 PD-L1, PD-L2, and OX40.
20. The method according to claim 10, wherein said first and said second cancer cytotoxic agents are administered simultaneously to within about 3 hours of each other.
21. Use of a therapeutically effective amount of a halogenated xanthene, a pharmaceutically acceptable salt or a C1-C4 alkyl ester thereof as a first cancer cytotoxic agent dissolved or dispersed in a pharmaceutically acceptable aqueous medium for treatment of a mammalian subject having hematologic, non-tumorous cancer cells, wherein said halogenated xanthene is maintained in said mammalian subject for a period of time sufficient to induce death of hematologic, non-tumorous cancer cells.
22. The use according to Claim 21 wherein said hematologic, non-tumorous cancer cells are leukemia, lymphoma or myeloma.
23. The use according to Claims 21 or 22 wherein hematologic, non-tumorous cancer cells, leukemia, lymphoma or myeloma is selected from the group consisting of acute B-cell or T-cell lymphoblastic leukemia, acute myeloid leukemia, non-Hodgkin's lymphoma, and Hodgkin's lymphoma.
24. The use according to Claim 21 wherein the use is carried out in vivo in said mammalian subject.
25. The use according to claims 21-24, wherein said mammalian subject is selected from the group consisting of a human, an ape, a monkey, a laboratory animal, a companion animal and a food animal.
26. The use according to claims 21-25, wherein said first cancer cytotoxic agent halogenated xanthene, pharmaceutically acceptable salt or C1-04 alkyl ester thereof is rose bengal, a pharmaceutically acceptable salt or C1-C4 alkyl ester thereof.
27. The use according to claims 21-26, wherein said rose bengal, a pharmaceutically acceptable salt or C1-C4 alkyl ester thereof is rose bengal disodium salt.
28. The use according to claims 21-27, wherein said pharmaceutically acceptable aqueous medium is an approximately isotonic aqueous solution.
29. The use according to claim 21 further comprising use of a second therapeutically effective amount of a second, differently-acting cancer cytotoxic agent dissolved or dispersed in a pharmaceutically acceptable medium for treatment of the mammalian subject having hematologic, non-tumorous cancer cells.
30. The use according to claim 29, wherein said second cancer cytotoxic agent is dissolved or dispersed in a pharmaceutically acceptable solid medium.
31. The use according to claim 30, wherein the pharmaceutically acceptable solid medium containing the second cancer cytotoxic agent is administered per os.
32. The use according to claim 29, wherein second cancer cytotoxic agent is a small molecule having a molecular weight of about 200 to about 1000 Da.
33. The use according to claim 30, wherein said small molecule exhibits synergy with said first cancer cytotoxic agent.
34. The use according to claim 30, wherein said second cancer cytotoxic agent is dissolved or dispersed in a pharmaceutically acceptable aqueous medium.
35. The use according to claim 34, wherein the pharmaceutically acceptable aqueous medium containing the second cancer cytotoxic agent is administered intravenously.
36. The use according to claim 35, wherein the second cancer cytotoxic agent comprises intact monoclonal antibodies or paratope-containing portions thereof.
37. The use according to claim 36, wherein said intact monoclonal antibodies or paratope-containing portions thereof are immune checkpoint protein inhibitors.
38. The use according to claim 37, wherein said immune checkpoint protein inhibitors bind to one or more proteinaceous materials selected from one or more of the group consisting of CTLA-4, PD-1, PD-L1, PD-L2, and 0X40.
39. The use according to claim 29, wherein said first and said second cancer cytotoxic agents are administered simultaneously to within about 3 hours of each other.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2019/062184 WO2021101521A1 (en) | 2019-11-19 | 2019-11-19 | Composition and method for treating hematologic cancers |
Publications (1)
Publication Number | Publication Date |
---|---|
CA3158221A1 true CA3158221A1 (en) | 2021-05-27 |
Family
ID=75980032
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA3158221A Pending CA3158221A1 (en) | 2019-11-19 | 2019-11-19 | Composition and method for treating hematologic cancers |
Country Status (5)
Country | Link |
---|---|
JP (1) | JP2023506609A (en) |
AU (1) | AU2019474803A1 (en) |
CA (1) | CA3158221A1 (en) |
MX (1) | MX2022005828A (en) |
WO (1) | WO2021101521A1 (en) |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7648695B2 (en) * | 1998-08-06 | 2010-01-19 | Provectus Pharmatech, Inc. | Medicaments for chemotherapeutic treatment of disease |
KR20140038382A (en) * | 2011-03-10 | 2014-03-28 | 프로벡투스 파마슈티컬스 인코포레이티드 | Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer |
CN109689056A (en) * | 2016-08-01 | 2019-04-26 | 亚尼塔公司 | Combination for treating cancer |
-
2019
- 2019-11-19 AU AU2019474803A patent/AU2019474803A1/en active Pending
- 2019-11-19 WO PCT/US2019/062184 patent/WO2021101521A1/en active Application Filing
- 2019-11-19 CA CA3158221A patent/CA3158221A1/en active Pending
- 2019-11-19 JP JP2022555613A patent/JP2023506609A/en active Pending
- 2019-11-19 MX MX2022005828A patent/MX2022005828A/en unknown
Also Published As
Publication number | Publication date |
---|---|
MX2022005828A (en) | 2022-07-04 |
WO2021101521A1 (en) | 2021-05-27 |
AU2019474803A2 (en) | 2022-07-14 |
AU2019474803A1 (en) | 2022-05-26 |
JP2023506609A (en) | 2023-02-16 |
AU2019474803A8 (en) | 2022-06-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230159640A1 (en) | Carrier-pd-l1 binding agent compositions for treating cancers | |
AU2005304973A1 (en) | Antibody induced cell membrane wounding | |
US20180303935A1 (en) | A nanomaterial complex comprising graphene oxide associated with a therapeutic agent and methods of use | |
US20220313822A1 (en) | Near-infrared (nir) photoimmunotherapy (pit) for the treatment of cancers using anti-cd25 antibody-phthalocyanine dye conjugate and anti-pd1 antibody | |
US11974980B2 (en) | In vitro and xenograft anti-tumor activity of a halogenated-xanthene against refractory pediatric solid tumors | |
KR20200088374A (en) | Methods of using targeted radiotherapy (TRT) to induce an anti-tumor immune response to immunotherapy | |
US11419844B2 (en) | Halogenated xanthene composition and method for treating hematologic cancers | |
BR112021001858A2 (en) | use of negatively charged particles in combination with cancer therapy to treat cancer or a proliferative disease | |
CA3158221A1 (en) | Composition and method for treating hematologic cancers | |
JP2018527402A (en) | SYD985 treatment of patients with T-DM1 refractory cancer | |
Dreicer et al. | A phase II trial of deferoxamine in patients with hormone-refractory metastatic prostate cancer | |
US20210100896A1 (en) | Methods and compositions for stimulating the immune system | |
US20220296712A1 (en) | Methods for treatment using phthalocyanine dye-targeting molecule conjugates | |
US20230302168A1 (en) | Dr5 radioimmunotherapy in the treatment of solid cancers | |
RU2794261C2 (en) | Immune-modifying particles for cancer treatment | |
US20210236418A1 (en) | Composition and Method for Oral Treatment of Leukemia | |
RU2802962C2 (en) | Compositions and methods of treatment of liver cancer | |
KR20230171854A (en) | Compositions and methods for oral treatment of leukemia | |
JP2022535816A (en) | Methods and compositions for treating cancer using collagen-bound drug carriers | |
CN117615791A (en) | Combination therapy using antibody drug conjugates | |
Sinn et al. | Albumin-Based Drug Delivery as Novel |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |
Effective date: 20231116 |